US20020156285A1

US20020156285A1 - Novel herbicides

Info

Publication number: US20020156285A1
Application number: US10/061,627
Authority: US
Inventors: Walter Kunz; Kurt Nebel
Original assignee: Individual
Current assignee: Individual
Priority date: 1998-04-28
Filing date: 2002-01-31
Publication date: 2002-10-24
Also published as: US6369002B1; AU746667B2; ID26810A; WO1999055693A3; WO1999055693A2; KR20010043132A; BR9910578A; AU3823599A; JP2002513014A; EP1076656A2

Abstract

Compounds of formula 1

R₁is hydrogen, fluorine, chlorine, bromine or methyl;

R₂is C₁-C₄alkyl, C₁-C₄halogenalkyl, halogen, hydroxy, C₁-C₄alkoxy, C₁-C₄halogenalkoxy, nitro, amino or cyano;

R₃, R₁₅to R₃₉and X₆to X₁₉are as defined in claim 1, and the agrochemically acceptable salts and stereoisomers of these compounds of formula I are suitable for use as herbicides.

Description

The present invention relates to new, herbicidally active, substituted n-pyridyl-nitrogen heterocycles, methods for the preparation thereof, compositions comprising these compounds, and the use thereof for weed control, especially in crops of cultivated plants, such as grain, cereals, maize, rice, cotton, soybeans, rape, sorghum, sugar cane, sugar beet, sunflowers, vegetables, plantations, and forage crops or for the inhibition of plant growth and for non-selective control of weeds.

N-Phenyl and N-pyridylpyrazole compounds and N-pyridyltetramethylenetriazolidinediones with a herbicidal action are described, for example, in EP-A-0 370 332, DE-A-3 917 469, DE-A-19 518 054, DE-A-19 530 606, U.S. Pat. Nos. 5,306,694 and 4,406,689. Also known as herbicides are N-pyridylimides, N-(2-pyridyl)pyridazinones and 3-phenyluracils, as described for example in WO 92/00976, JP-A-58-213 776 and EP-A-0 438 209. N-(Phenyl)tetrahydroimidazoles with a herbicidal action are described for example in U.S. Pat. No. 5,112,383.

New substituted n-pyridyinitrogen heterocycles have now been found with herbicidal and growth-inhibiting properties.

Accordingly, the invention relates to compounds of formula I

R ₁is hydrogen, fluorine, chlorine, bromine or methyl;

R ₂is C₁-C₄alkyl, C₁-C₄halogenalkyl, halogen, hydroxy, C₁-C₄alkoxy, C₁-C₄halogenalkoxy, nitro, amino or cyano;

R ₃is cyano or R₄C(O)—;

R ₄is hydrogen, fluorine, chlorine, C₁-C₈alkyl, C₂-C₈alkenyl, C₂-C₈alkinyl, C₃-C₆cycloalkyl, C₁-C₈halogenalkyl, cyano-C₁-C₄alkyl, C₂-C₈halogenalkenyl, C₁-C₄alkoxy-C₁-C₄alkyl, C₃-C₆alkenyloxy-C₁-C₄alkyl, C₁-C₄alkylthio-C₁-C₄alkyl, phenyl, phenyl substituted once to three times by halogen, C₁-C₄alkyl or C₁-C₄halogenalkyl, benzyl, benzyl substituted once to three times on the phenyl ring by halogen, C₁-C₄alkyl or C₁-C₄halogenalkyl; or

R ₃is R₅X₁C(O)—;

X ₁is oxygen, sulfur

R ₅is hydrogen, C₁-C₈alkyl, C₃-C₈alkenyl, C₃-C₈alkinyl, C₃-C₆cycloalkyl, C₃-C₆cycloalkyl-C₁-C₆alkyl, C₁-C₈halogenalkyl, C₃-C₈halogenalkenyl, cyano-C₁-C₄alkyl, C₁-C₄alkoxy-C₁-C₄alkyl, C₃-C₆alkenyloxy-C₁-C₄alkyl, (oxiranyl)-CH₂—, oxetanyl, C₁-C₄alkylthio-C₁-C₄alkyl, phenyl, phenyl substituted once to three times by halogen, C₁-C₄alkyl or C₁-C₄halogenalkyl, benzyl, benzyl substituted once to three times on the phenyl ring by halogen, C₁-C₄alkyl or C₁-C₄-

R ₈is hydrogen, C₁-C₈alkyl, C₃-C₈alkenyl, C₃-C₈alkinyl, C₃-C₆cycloalkyl, C₁-C₈halogenalkyl, C₃-C₈halogenalkenyl, cyano-C₁-C₄alkyl, C₁-C₄alkoxy-C₁-C₄alkyl, C₃-C₆alkenyloxy-C₁-C₄alkyl, (oxiranyl)-CH₂—, oxetanyl, C₁-C₄alkylthio-C₁-C₄alkyl, phenyl, phenyl substituted once to three times by halogen, C₁-C₄alkyl or C₁-C₄halogenalkyl, benzyl, benzyl substituted once to three times on the phenyl ring by halogen, C₁-C₄alkyl or C₁-C₄halogenalkyl, or phenyl-C₂-C₆alkyl;

R ₆, R₇, R₉and R₁₀are independently of one another hydrogen, C₁-C₈alkyl, C₃-C₈alkenyl, C₃-C₈alkinyl, C₁-C₈halogenalkyl or benzyl; or

R ₃is B₁—C₁-C₈alkyl, B₁—C₂-C₈alkenyl, B₁—C₂-C₈alkinyl, B₁—C₁-C₈halogenalkyl, B₁—C₂-C₈halogenalkenyl, B₁—C₁-C₄alkoxy-C₁-C₄alkyl, B₁—C₁-C₄alkylthio-C₁-C₄alkyl or B₁—C₃-C₆cycloalkyl;

B ₁is hydrogen, cyano, hydroxy, Cl-C₈alkoxy, C₃-C₈alkenyloxy, R₁₁X₃C(O)—, C₁-C₄alkylcarbonyl or C₁-C₄halogenalkylcarbonyl;

X ₃has the same meaning as X₂;

R ₁₁has the same meaning as R₈; or

R ₃is B₂—C(R₁₂)═CH—;

B ₂is nitro, cyano or R₁₃X₄C(O)—;

R ₁₂is cyano or R₁₄X₅C(O)—;

X ₄and X₅have the same meaning as X₂; and

R ₁₃and R₁₄have the same meaning as R₈;

R ₁₅is C₁-C₃alkyl, C₁-C₃halogenalkyl or amino;

R ₁₆is C₁-C₃halogenalkyl, C₁-C₃alkyl-S(O)_n1, C₁-C₃halogenalkyl-S(O)_n1or cyano; or

R ₁₆and R₁₅together form a C₃- or C₄alkylene or C₃- or C₄alkenylene bridge which may be substituted by halogen, C₁-C₃halogenalkyl or cyano;

n ₁is 0, 1 or 2;

R ₁₇is hydrogen, C₁-C₃alkyl, halogen, C₁-C₃halogenalkyl or cyano; or

R ₁₇and R₁₆together form a C₃- or C₄alkylene or C₃- or C₄alkenylene bridge which may be substituted by halogen, Cl-C₃halogenalkyl or cyano;

R ₁₈is hydrogen, C₁-C₃alkyl, halogen or cyano;

R ₁₉is C₁-C₃halogenalkyl; or

R ₁₉and R₁₈together form a C₃- or C₄alkylene or C₃- or C₄alkenylene bridge which may be substituted by halogen, C₁-C₃halogenalkyl or cyano;

R ₂₀is hydrogen or C₁-C₃alkyl or halogen; or

R ₂₀and R₁₉together form a C₃- or C₄alkylene or C₃- or C₄alkenylene bridge which may be substituted by halogen, C₁-C₃halogenalkyl or cyano;

R ₂₁is hydrogen, C₁-C₃alkyl, halogen, C₁-C₃halogenalkyl, R₄₀O—, R₄₁S(O)_n2, R₄₂(R₄₃)N,

R ₄₅(R₄₆)N—C(R₄₄)═N—, hydroxy, nitro or N≡C—S—;

R ₄₀is C₁-C₃alkyl, C₁-C₃halogenalkyl, C₂-C₄alkenyl, C₃- or C₄alkinyl or C₁-C₅alkoxycarbonyl-C₁-C₄alkyl;

R ₄₁is C₁-C₄alkyl or C₁-C₄halogenalkyl;

n ₂is 0, 1 or 2;

R ₄₂is hydrogen, C₁-C₄alkyl, C₁-C₄halogenalkyl, C₃-C₆cycloalkyl, OHC— or C₁-C₄alkylcarbonyl;

R ₄₃, R₄₄, and R₄₆are independently of one another hydrogen or C₁-C₄alkyl;

R ₄₅is C₁-C₄alkyl;

R ₂₂is hydrogen, C₁-C₄alkyl, halogen, C₁-C₄halogenalkyl, C₂-C₄alkenyl, C₃-C₅halogenalkenyl, C₃- or C₄alkinyl, C₁-C₄alkoxy, C₁-C₄alkylcarbonyl, C₁-C₄halogenalkylcarbonyl, C₂-C₄alkenylcarbonyl, C₂-C₄halogenalkenylcarbonyl, C₂-C₄alkinylcarbonyl, C₂-C₄halogenalkinyl-carbonyl, C₁-C₄alkylcarbamoyl, C₁-C₄alkylS(O)_n3, C₃- or C₄alkinylS(O)_n3, OHC—, nitro, amino, cyano or N≡C—S—;

n ₃is 0, 1 or 2;

R ₂₃and R₂₄independently of one another are hydrogen, C₁-C₄alkyl, halogen, C₁-C₄halogen-alkyl or cyano;

R ₂₅and R₂₆are independently of one another hydrogen, methyl, halogen, hydroxy or ═O;

R ₂₇and R₂₈are independently of one another hydrogen, C₁-C₄alkyl or C₁-C₄halogenalkyl;

R ₂₉and R₃₀are independently of one another hydrogen, C₁-C₃alkyl or halogen;

R ₃₁and R₃₂independently of one another are hydrogen or C₁-C₄alkyl; or

R ₃₁and R₃₂together form the group

R ₄₇and R₄₈are independently of one another C₁-C₄alkyl; or

R ₄₇and R₄₈together form a C₄or C₅alkylene bridge;

R ₃₃is hydrogen or C₁-C₃alkyl; or

R ₃₃together with R₃₂forms a C₃-C₅alkylene bridge which may be broken by oxygen and/or substituted by halogen, C₁-C₄alkyl, C₂-C₄alkenyl, C₁-C₃alkylcarbonyloxy, C₁-C₃alkyl-sulfonyloxy, hydroxy or ═O;

R ₃₄, R₃₅, R₃₆and R₃₇are independently of one another hydrogen, C₁-C₃alkyl, C₃- or C₄alkenyl or C₃-C₅alkinyl; or

R ₃₄and R₃₅on the one hand and R₃₆and R₃₇on the other each form a C₂-C₅alkylene or C₃-C₅alkenylene bridge, which may be broken by oxygen, —C(O)—, sulfur, or —S(O)₂—;

R ₃₈is hydrogen, C₁-C₄alkyl, C₁-C₄halogenalkyl, C₃- or C₄alkenyl or C₃- or C₄alkinyl;

R ₃₉is hydrogen, C₁-C₄alkyl, C₁-C₃alkoxy-C₁- or -C₂alkyl, C₁-C₄halogenalkyl, C₃- or C₄alkenyl, C₃- or C₄halogenalkenyl or C₃- or C₄alkinyl; or

R ₃₉and R₃₈together form a C₃-C₅alkylene bridge; and

X ₆, X₇, X₈, X₉, X₁₀, X₁₁, X₁₂, X₁₃, X₁₄, X₁₅, X₁₆, X₁₇, X₁₈and X₁₉are independently of one another oxygen or sulfur,

and the agrochemically acceptable salts and stereoisomers of these compounds of formula I.

In the definitions listed hereinbefore, halogen is taken to mean iodine, preferably fluorine, chlorine and bromine. The alkyl, alkenyl and alkinyl groups mentioned in the substituent definitions may be straight-chained or branched, as is also the case with the alkyl, alkenyl and alkinyl part of the alkylcarbonyl, alkylcarbonyloxy, alkylcarbonylalkyl, alkenyloxy, alkenyloxyalkyl, alkenylcarbonyl, alkinylcarbonyl, alkylcarbamoyl, hydroxyalkyl, cyanoalkyl, alkoxyalkyl, alkylthio, alkylthioalkyl, alkylthio-C(O)—, alkylS(O) _n3, alkylsulfonyloxy, alkylaminocarbonyl, dialkylaminocarbonyl, alkylcarbonylalkyl, B₁alkyl, Blalkenyl, B₁alkinyl, HOC(O)alkyl, phenylalkyl and R₈X₂C(O)—C₁-C₆alkyl groups. Alkyl groups are for example methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl and the various isomeric pentyl, hexyl, heptyl and octyl radicals. Preferred are methyl, ethyl, n-propyl, isopropyl and n-butyl. Examples of alkenyls are vinyl, allyl, methallyl, 1-methylvinyl, but-2-en-1-yl, pentenyl, 2-hexenyl, 3-heptenyl and 4-octenyl, preferably alkenyl radicals with a chain length of 3 to 5 carbon atoms. Examples of alkinyls are ethinyl, propargyl, 1-methylpropargyl, 3-butinyl, but-2-in-1-yl, 2-methylbutin-2-yl, but-3-in-2-yl, 1-pentinyl, pent-4-in-1-yl or 2-hexinyl, preferably alkinyl radicals with a chain length of 2 to 4 carbon atoms. Alkyl groups substituted once or more, especially once to three times, by halogen are suitable as the halogenalkyl, the halogen being iodine, especially fluorine, chlorine and bromine, for example fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2-chloroethyl, 2,2-dichloroethyl, 2,2,2-trifluoroethyl, 2,2,2-trichloroethyl and pentafluoroethyl. Suitable halogenalkenyls are alkenyl groups substituted once or more by halogen, the halogen being bromine, iodine and especially fluorine and chlorine, for example 2- and 3-fluoropropenyl, 2- and 3-chloropropenyl, 2- and 3-bromopropenyl, 2,3,3-trifluoropropenyl, 3,3,3-trifluoropropenyl, 2,3,3-trichloropropenyl, 4,4,4-trifluorobut-2-en-1-yl and 4,4,4-trichlorobut-2-en-1-yl. Of the alkenyl radicals substituted once, twice or three times by halogen, those with a chain length of 3 or 4 carbon atoms are preferred. The alkenyl groups may be substituted by halogen on saturated or unsaturated carbon atoms. Suitable halogenalkinyls are for example alkinyl groups substituted by halogen, the halogen being bromine, iodine and especially fluorine and chlorine, for example 3-fluoropropinyl, 3-chloropropinyl, 3-bromopropinyl, 3,3,3-trifluoropropinyl and 4,4,4-trifluorobut-2-in-1-yl. Alkylsulfonyl is for example methylsulfonyl, ethylsulfonyl, propylsulfonyl, isopropylsulfonyl, n-butylsulfonyl, isobutylsulfonyl, sec-butylsulfonyl, tert-butylsulfonyl; preferably methylsulfonyl and ethylsulfonyl. Halogenalkylsulfonyl is for example fluoromethylsulfonyl, difluoromethylsulfonyl, trifluoromethylsulfonyl, chloromethylsulfonyl, trichloromethylsulfonyl, 2-fluoroethylsulfonyl, 2,2,2-trifluoroethylsulfonyl and 2,2,2-trichloroethylsulfonyl. Halogenalkenylsulfonyl is for example 2- and 3-fluoropropenylsulfonyl, 2- and 3-chloropropenylsulfonyl, 2- and 3-bromopropenylsulfonyl, 2,3,3-trifluoropropenylsulfonyl, 2,3,3-trichloropropenylsulfonyl, 4,4,4-trifluorobut-2-en-1-yl-sulfonyl and 4,4,4-trichlorobut-2-en-1-yl-sulfonyl. Cyanoalkyl is for example cyanomethyl, cyanoethyl, cyanoeth-1-yl and cyanopropyl. Hydroxyalkyl is for example hydroxymethyl, 2-hydroxyethyl and 3-hydroxypropyl. Alkylamino is for example methylamino, ethylamino and the isomeric propyl and butylamino. Dialkylamino is for example dimethylamino, diethylamino and the isomeric dipropyl and dibutylamino. Halogenalkylamino is for example chloroethylamino, trifluoroethylamino and 3-chloropropylamino. Di(halogenalkyl)amino is for example di(2-chloroethyl)-amino. Alkylcarbonyl is in particular acetyl and propionyl. Halogenalkylcarbonyl is in particular trifluoroacetyl, trichloroacetyl, 3,3,3-trifluoropropionyl and 3,3,3-trichloropropionyl. Alkenylcarbonyl is in particular vinylcarbonyl, allylcarbonyl, methallylcarbonyl, but-2-en-1-yl-carbonyl, pentenylcarbonyl and 2-hexenylcarbonyl. Alkinylcarbonyl is in particular acetylenecarbonyl, propargylcarbonyl, 1-methyl-propargylcarbonyl, 3-butinylcarbonyl, but-2-in-1-yl-carbonyl and pent-4-in-1-yl-carbonyl. Alkoxy is for example methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy and tert-butoxy; preferably methoxy, ethoxy and isopropoxy. Alkenyloxy is for example allyloxy, methallyloxy and but-2-en-1-yloxy. Alkinyloxy is for example propargyloxy and 1-methylpropargyloxy. Alkoxyalkyl is for example methoxymethyl, methoxyethyl, ethoxymethyl, ethoxyethyl, n-propoxymethyl, n-propoxyethyl, isopropoxymethyl and isopropoxyethyl. Alkenyloxy is for example allyloxyalkyl, methallyloxyalkyl and but-2-en-1-yloxyalkyl. Alkoxycarbonyl is for example methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, isopropoxycarbonyl and n-butoxycarbonyl, preferably methoxycarbonyl and ethoxycarbonyl. Alkenyloxycarbonyl is for example allyloxycarbonyl, methallyloxycarbonyl, but-2-en-1-yl-oxycarbonyl, pentenyloxycarbonyl and 2-hexenyloxycarbonyl. Alkinyloxycarbonyl is for example propargyloxycarbonyl, 3-butinyloxycarbonyl, but-2-in-1-yl-oxycarbonyl and 2-methylbutin-2-yl-oxycarbonyl. Alkoxyalkoxycarbonyl is for example methoxymethoxycarbonyl, ethoxymethoxycarbonyl, ethoxyethoxycarbonyl, propoxymethoxycarbonyl, propoxyethoxycarbonyl, propoxypropoxycarbonyl and butoxyethoxycarbonyl. Halogenalkoxy is for example fluoromethoxy, difluoromethoxy, trifluoromethoxy, 2,2,2-trifluoroethoxy, 1,1,2,2-tetrafluoroethoxy, 2-fluoroethoxy, 2-chloroethoxy and 2,2,2-trichloroethoxy. The cycloalkyl radicals suitable as substituents are for example cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. The cycloalkoxycarbonyl radicals suitable as substituents are for example cyclopropoxycarbonyl, cyclobutoxycarbonyl, cyclopentoxycarbonyl and cyclohexyloxycarbonyl. Alkylthio is for example methylthio, ethylthio, propylthio and butylthio, as well as the branched isomers thereof. Alkylthioalkyl is for example methylthioethyl, ethylthioethyl, methylthiopropyl and ethylthiopropyl. Halogenalkylthiocarbonyl is for example fluoromethylthiocarbonyl, difluoromethylthiocarbonyl, trifluoromethylthiocarbonyl, 2,2,2-trifluoroethylthiocarbonyl, 1,1,2,2-tetrafluoroethylthiocarbonyl, 2-fluoroethylthiocarbonyl, 2-chloroethylthiocarbonyl and 2,2,2-trichloroethylthiocarbonyl. Corresponding meanings may also be ascribed to the substituents in the listed definitions, such as, for example, halogenalkenylcarbonyl, halogenalkinylcarbonyl, R₄₀O—, R₄C(O)—, R₁₁X₃C(O)—, R₁₃X₄C(O)—, R₁₄X₅C(O)—, R₅X₁C(O)—, R₈X₂C(O)-alkyl, R₈X₂C(O)-cycloalkyl, R₄₁S(O)₂—,

R ₄₂(R₄₃)N—, R₄₅(R₄₆)N—C(R₄₄)═N—, B₁alkyl, B₁alkenyl, B₁alkinyl, B₁halogenalkyl, B₁halogenalkenyl, B₁alkoxyalkyl, B₁alkylthioalkyl, B₁cycloalkyl and B₂—C(R₁₂)═CH—.

In the definition of R ₅, the groups

mean that the C ₁-C₆alkyl-C(O)— or C₁-C₆alkylene chain is in addition substituted by phenyl (C₆H₅) on one of the 4 or 6 carbon atoms, wherein the phenyl ring is substituted once to three times by halogen, C₁-C₄alkyl or C₁-C₄halogenalkyl, and the alkylene chain may be straight-chained or branched and may, for example, be methylene, ethylene, methylethylene, propylene, 1-methylpropylene and butylene. In the definitions cyanoalkyl, alkylcarbonyl, alkenylcarbonyl, halogenalkenylcarbonyl, alkinylcarbonyl, alkoxycarbonyl, alkoxycarbonylalkyl and halogenalkylcarbonyl, the cyano- and carbonyl carbon atoms are not included in the upper and lower limits of the carbon number. L in the reagents of formulae XII, XXI, XXIVa, XXIVb and XXXV is a leaving group, such as halogen, for example, preferably chlorine, bromine or iodine, C₁-C₃alkyl- or arylsulfonyloxy, preferably CH₃SO₂O— or

or C ₁-C₆alkylcarbonyloxy, preferably acetyloxy. L₁in the reagent of formula XIII is a leaving group such as, for example, HOS(O)₂O—,

L ₂in the reagents of formulae XXVa and XXVc is a leaving group such as, for example, hydroxy, C₁-C₄alkoxy or halogen, preferably chlorine, bromine or iodine. L₃in the reagent of formula XXXI is a leaving group such as chlorine or bromine, trichloromethoxy or

L ₄in the compounds of formulae II and III (reaction schemes 1 and 2) is a leaving group such as, for example, halogen, typically fluorine, chlorine or bromine or C₁-C₄alkyl- or phenylsulfonyl or C₁-C₄alkyl-, C₁-C₄halogenalkyl- or phenylsulfonyloxy. R₃₃together with R₃₂(group W₇) forms a C₃-C₅alkylene bridge which may be broken for example by oxygen and substituted by ═O, and is illustrated by way of example in Tables 127 (compound of formula I₁₂₇), 130 (compound of formula I₁₃₀), 136 (compound of formula I₁₃₆) and 137 (compound of formula I₁₃₇).

The invention relates also to the salts which the compounds of formula I with acidic hydrogen, especially the derivatives with carboxylic acid groups (for example, carboxyl-substituted alkyl, alkylene, alkenyl, alkinyl, alkoxyalkyl, alkylthioalkyl and cycloalkyl groups) may form with bases. These salts are, for example, alkali metal salts, such as sodium and potassium salts; earth alkali metal salts, such as calcium and magnesium salts; ammonium salts, i.e. unsubstituted ammonium salts and monosubstituted or polysubstituted ammonium salts, such as triethylammonium and methylammonium salts; or salts with other organic bases. Salt-forming alkali metal and alkaline earth metal bases include the hydroxides of lithium, sodium, potassium, magnesium or calcium, those of sodium and potassium being especially preferred. Suitable salt-forming substances are described for example in WO 97/41112. Examples of amines suitable for forming ammonium salts are ammonia, as well as primary, secondary, and tertiary C ₁-C₁₈alkylamines, C₁-C₄hydroxyalkylamines and C₂-C₄alkoxyalkylamines, typically methylamine, ethylamine, n-propylamine, isopropylamine, the four isomeric butylamines, n-amylamine, isoamylamine, hexylamine, heptylamine, octylamine, nonylamine, decylamine, pentadecylamine, hexadecylamine, heptadecylamine, octadecylamine, methyl ethylamine, methyl isopropylamine, methyl hexylamine, methyl nonylamine, methyl pentadecylamine, methyl octadecylamine, ethyl butylamine, ethyl heptylamine, ethyl octylamine, hexyl heptylamine, hexyl octylamine, dimethylamine, diethylamine, di-n-propylamine, diisopropylamine, di-n-butylamine, di-n-amylamine, diisoamylamine, dihexylamine, diheptylamine, dioctylamine, ethanolamine, n-propanolamine, isopropanolamine, N,N-diethanolamine, N-ethylpropanolamine, N-butylethanolamine, allylamine, n-butenyl-2-amine, n-pentenyl-2-amine, 2,3-dimethylbutenyl-2-amine, dibutenyl-2-amine, n-hexenyl-2-amine, propylenediamine, trimethylamine, triethylamine, tri-n-propylamine, triisopropylamine, tri-n-butylamine, triisobutylamine, tri-sec-butylamine, tri-n-amylamine, methoxyethylamine and ethoxyethylamine; heterocyclic amines such as pyridine, quinoline, isoquinoline, morpholine, thiomorpholine, piperidine, pyrrolidine, indoline, quinuclidine and azepine; primary arylamines such as anilines, methoxyanilines, ethoxyanilines, o-, m- and p-toluidines, phenylenediamines, benzidines, naphthylamines and o-, m- and p-chloroanilines; but especially triethylamine, isopropylamine and diisopropylamine.

The salts of compounds of formula I with basic groups, especially with basic pyridyl and pyrazolyl rings (W3 and W4), or of derivatives with amino groups, e.g. amino, alkylamino and dialkylamino groups in the definition of R ₂, W₁or W₃(R₁₅, R₂₁, R₂₂) are, for example, salts with inorganic and organic acids, for example hydrogen halides, such as hydrofluoric acid, hydrochloric acid, hydrobromic acid or hydriodic acid, as well as sulfuric acid, phosphoric acid, nitric acid and organic acids, such as acetic acid, trifluoracetic acid, trichloroacetic acid, propionic acid, hydroxyethanoic acid, thiocyanic acid, citric acid, benzoic acid, oxalic acid, formic acid, benzenesulfonic acid, p-toluenesulfonic acid and methanesulfonic acid The presence of at least one asymmetric carbon atom in the compounds of formula I, for example in substituent R₃=R₅X₁C(O)—, wherein R₅is a branched alkyl, alkenyl, halogenalkyl or alkoxyalkyl group, or R₃=B₁—C₃-C₆cycloalkyl, wherein for example B₁is C₁-C₈alkoxy or R₁₁X₃C(O)—, means that the compounds may occur both in single optically active isomers and also in the form of racemic mixtures. In the present invention, the active substances of formula I are understood to include both the pure enantiomers and the racemates or diastereomers. If an aliphatic C═C double bond is present (e.g. in substituent R₃=B₂—C(R₁₂)═CH—), then geometric isomerism may occur. The present invention also relates to these isomers.

Compounds of formula I are preferred wherein R ₂is methyl, halogen, hydroxy, nitro, amino or cyano.

Also preferred are compounds of formula I wherein W is the group

and R ₁₅, R₁₆, R₁₇, X₆and X₇are as defined under formula I. Especially preferred are those compounds wherein R₁₅is methyl; R₁₆is trifluoromethyl; R₁₇is hydrogen; and X₆and X₇are oxygen. Likewise preferred are compounds of formula I wherein R₁is fluorine or chlorine; R₂is chlorine, bromine or cyano; and R₃is R₅X₁C(O)—, wherein R₅has the meaning defined under formula I; and X₁is oxygen or sulfur. Of these compounds, those wherein R₂is chlorine are especially important.

The method described in the invention for the preparation of compounds of formula I,

wherein R ₁, R₂, R₃, A and W are as defined under formula 1, is carried out by analogy with known methods, such as those described for example in WO 97/00246, WO 96/01254 and International Patent Application Number PCT/EP 97/06243, and comprises treating a compound of formula II

wherein R ₁, R₂and W have the meanings indicated, and L₄is a leaving group such as halogen, either

a) in a suitable solvent, where appropriate in the presence of a base such as a trialkylamine, a palladium or nickel catalyst and a compound of formula V

R₅—OH (V),

wherein R ₅is hydrogen or C₁-C₄alkyl, in an autoclave under positive pressure with carbon monoxide, or

b) in a suitable solvent in the presence of a tertiary amine, a palladium catalyst, and an olefin by means of the Heck reaction, or under said conditions by means of reaction with a Grignard reagent of formula Va

R₃—Mg-halogenide (Va),

wherein R ₃is B₁—C₁-C₈alkyl, B₁—C₂-C₈alkenyl, B₁—C₂-C₈alkinyl, B₁—C₁-C₈halogenalkyl, B₁-C₂-C₈halogenalkenyl, B₁—C₁-C₄alkoxy-C₁-C₄alkyl, B₁—C₁-C₄alkylthio-C₁-C₄alkyl or B₁—C₃-C₆cycloalkyl and B₁is as defined under formula I, or in an inert solvent and in the presence of a catalyst, such as palladium-bis-triphenylphosphine dichloride (Pd(C₆H₅)₂Cl₂), in a manner analogous to that described in Synleft 1998, 1185, with a tin compound of formula Vb

(R₃)₄Sn (Vb),

wherein R ₃has the meaning indicated, or

c) where applicable in an inert solvent at reaction temperatures of 20-300° C. subjecting it to a cyanidation reaction, e.g. with an alkali metal cyanide or a cyanide whose metal ion belongs to the first or second subgroup of the periodic system, such as copper cyanide, in a manner analogous to that described in J. Het. Chem. 11, 397 (1974), or

d) first oxidizing it in a suitable solvent to form a compound of formula IV

and treating this in an inert solvent with dimethylcarbamoyl chloride and a cyanidation reagent, and then where applicable further functionalizing it according to the definitions of A and R ₃.

wherein R ₁, R₂, R₃and A are as defined under formula I, W is a W₁group

(W ₁), and R₁₅, R₁₆, R₁₇, X₆and X₇are as defined under formula I, corresponding to a compound of formula Ia in reaction scheme 2, is carried out by analogy with the known methods such as those described for example in EP-A-0 438 209 or DE-OS-19 604 229, and comprises reacting a compound of formula III

wherein R ₁, R₂and R₃have the meanings indicated, and L₄is a leaving group, such as halogen, for example fluorine, chlorine or bromine, in the presence of an inert solvent and ammonia if necessary in an autoclave at temperatures of −10 to 180° C. to form a compound of formula VI

reacting this in the presence of a base and a solvent

a) with a chloroformate of formula VII

wherein X ₆is as defined under formula I, to form a compound of formula VIII

b) with oxalyl chloride, phosgene or thiophosgene to form a compound of formula IX

followed by cyclization of a compound of formula VIII or IX in the presence of 0.1-1.5 equivalents of a base in an inert solvent with an enamine dervivative of formula X

wherein R ₁₆and R₁₇are as defined under formula I, and X₇is oxygen, and a resulting compound of formula XI

wherein R ₁, R₂, R₃, R₁₆, R₁₇, X₆and X₇have the meanings indicated, and further reacting this compound in the presence of an inert solvent and a base with

c) a compound of formula XII

R₁₅—L (XII),

wherein R ₁₅is C₁-C₃alkyl or C₁-C₃halogenalkyl, and L is a leaving group, or

d) with a hydroxylamine derivative of formula XIII

NH₂—L₁ (XIII),

wherein L ₁is a leaving group, and subsequently performing if necessary oxidation (A

wherein R ₁, R₂, R₃, and A are as defined under formula I, W is a W₂group

(W ₂), and R₁₈, R₁₉, R₂₀, and X₈areas defined under formula I, corresponding to a compound of formula Ib in reaction scheme 3, is carried out by analogy with known methods, such as those described for example in DE-A-4 423 934 and JP-A-58 213 776, and comprises either

a) reacting a compound of formula III,

wherein R ₁, R₂and R₃have the meanings indicated, and L₄is a leaving group such as halogen, for example fluorine, chlorine or bromine, with hydrazine, preferably in an amphiprotic solvent, to form a compound of formula XIV

further reacting this with a compound of formula XV or XVa

wherein R ₁₈and R₁₉have the meanings defined under formula 1, and Hal in a compound of formula XVa is chlorine or bromine, or

b) first diazotizing a compound of formula VI,

wherein R ₁, R₂and R₃have the meanings indicated, then further reacting it with a compound of formula XVI

wherein R ₁₈and R₁₉have the meanings indicated, and obtaining a compound of formula XVII

which if necessary is cyclized in the presence of a base, such as 4-dimethylaminopyridine and a compound of formula XVIII

wherein R ₂₀has the meaning indicated, and X₈is oxygen, and subsequently performing if

wherein R ₁, R₂, R₃and A are as defined under formula I, W is a W₇group

(W ₇), and R₃₁, R₃₂, R₃₃, and X₈are as defined under formula I, corresponding to a compound of formula Ig in reaction scheme 4, is carried out by analogy with known methods, such as those described for example in EP-A-0 272 594, EP-A-0 493 323, DE-A-3 643 748, WO 95/23509, U.S. Pat. Nos. 5,665,681 and 5,661,109, and comprises for example either

a) reacting a compound of formula VIIIa

in the presence of a solvent and a base, or

b) a compound of formula IXa

if necessary in a suitable solvent, wherein the radicals R ₁, R₂, R₃and X₁₄in compounds of formula VIIIa and IXa have the meanings indicated, with a compound of formula XIX

wherein R ₃₁, R₃₂, R₃₃and X₁₃have the meanings indicated, and obtaining a compound of formula XX

cyclizing this in the presence of a suitable solvent and a base and then where applicable

c) if R ₃₃is hydrogen, reacting it with a compound of formula XXI

R₃₃—L (XXI),

wherein R ₃₃is C₁-C₃alkyl, and L is a leaving group, and subsequently performing if necessary oxidation

and thionization.

wherein R ₁, R₂, R₃and A are as defined under formula I, W is a W₈group

(W ₈), and R₃₄, R₃₅, X₁₅, and X₁₆are as defined under formula I, corresponding to a compound of formula Ih in reaction scheme 5, is carried out by analogy with known methods, such as those described for example in EP-A-0 210 137, DE-A-2 526 358, EP-A-0 075 267 and EP-A-0 370 955, and comprises

a) reacting a compound of formula VIIIb

in the presence of a solvent and a base, or

b) a compound of formula IXb

wherein the radicals R ₁, R₂, R₃and X₁₅in compounds of formula VIIIb and IXb have the meanings indicated, if necessary in a suitable solvent, with a compound of formula XXII

wherein R ₃₄, R₃₅, and X₁₆have the meanings indicated, and obtaining a compound of formula XXIII

c) if R ₃₄and/or R₃₅are/is hydrogen, further reacting it with a compound of formula XXIVa or XXIVb

R₃₄—L (XXIVa)

or

R₃₅—L (XXIVb),

wherein R ₃₄and R₃₅are independently C₁-C₃alkyl, and L is a leaving group, or with a Michael acceptor, and then if necessary oxidizing

and thionizing it.

wherein R ₁, R₂, R₃and A are as defined under formula I, W is a W₃group

(W ₃), and R₂₁, R₂₂, and R₂₃are as defined under formula I, corresponding to a compound of formula Ic in reaction scheme 6, is carried out by analogy with known methods, such as those described for example in WO 97/07114, U.S. Pat. No. 5,306,694, DE-A-3 832 348, EP-A-0 257 479 and EP-A-0 500 209, and comprises condensing a compound of formula XIV

wherein R ₁, R₂and R₃have the meanings indicated, for example

a) with a compound of formula XXV

wherein R ₂₁is hydrogen, C₁-C₃alkyl or C₁-C₃halogenalkyl; R₂₂is hydrogen, C₁-C₄alkyl, C₁-C₄halogenalkyl, C₂-C₄alkenyl, C₃-C₅halogenalkenyl or C₃- or C₄alkinyl; and R₂₃is hydrogen, C₁-C₄alkyl or C₁-C₄halogenalkyl, if necessary in the presence of an acidic, basic or bifunctional catalyst such as p-toluenesulfonic acid, for example, or

b) with a compound of formula XXVa

wherein R ₂₂and R₂₃have the meanings indicated, and L₂is a suitable leaving group, to form a compound of formula XXVI

and further functionalizing the pyrazolone group in accordance with the definition of R ₂₁in a manner analogous to known methods, for example using a halogenation agent such as phosphorus oxychloride, to form the corresponding halogen derivative of formula Ic

wherein R ₁, R₂, R₃, R₂₂and R₂₃have the meanings indicated, and R₂₁is halogen, and subsequently performing if necessary oxidation

wherein R ₁, R₂R₃and A are as defined under formula I, W is a W₄group

(W ₄), and R₂₄, R₂₅, R₂₆are as defined under formula I, corresponding to formula Id in reaction scheme 7, is carried out by analogy with known methods such as those described for example in EP-A-0 370 332, EP-A-0 370 955 or DE-A-3 917 469, and comprises condensing a compound of formula XIV

wherein R ₁, R₂and R₃have the meanings indicated,

a) with a compound of formula XXVb

wherein R ₂₅and R₂₆have the meanings indicated, and R₂₄is hydrogen, C₁-C₄alkyl or C₁-C₄halogenalkyl, if necessary in the presence of a catalyst, or

b) with a compound of formula XXVc

wherein R ₂₅and R₂₆have the meanings indicated, and L₂is a suitable leaving group, to form a compound of formula XXVIa

and treating this compound with a halogenation agent, such as phosphoroxy halogenide or thionyl halogenide, and obtaining a compound of formula Id

wherein R ₁, R₂, R₃, R₂₅and R₂₆have the meanings indicated and R₂₄is halogen, and reacting this compound if necessary with a cyanide of formula XXVII

M(CN)_s (XXVII),

wherein M is an ammonium cation, alkali metal ion or metal ion of the first or second subgroup of the periodic system, and s is the number 1 or 2, where applicable in the presence of an alkali metal iodide (R ₂₄=cyano; reaction scheme 7), and subsequently performing if necessary oxidation

wherein R ₁, R₂, R₃and A are as defined under formula I, W is a W₅

(W ₆) group, and R₂₇, R₂₈, R₂₉, R₃₀, and X₉to X₁₂are as defined under formula I, corresponding to compounds of formula Ie and If in reaction scheme 8, is carried out by analogy with known methods, such as those described for example in DE-A-3 917 469, WO 92/00976, U.S. Pat. No. 5,069,711 and EP-A-0 260 228, and comprises for example

a) reacting a compound of formula XXVIII

b) a compound of formula XXVIIIa

wherein radicals R ₂₇to R₃₀in compounds of formulae XXVIII and XXVIIIa have the meanings indicated, with a compound of formulae VI

wherein R ₁, R₂and R₃have the meanings indicated, in an inert solvent in the presence of a C₁-C₄alkylcarboxylic acid at temperatures of 20° to 200° C. and reacting the resulting compounds of formulae Ie and If

wherein R ₁to R₃and R₂₇to R₃₀have the meanings indicated, and X₉to X₁₂are oxygen, if necessary with the aid of a suitable sulfur reagent to form the corresponding thiono compound of formulae Ie and If, wherein X₉and/or X₁₀, X₁₁, X₁₂, are sulfur, and oxidizing the said compound

reaction scheme 8).

The method described in the invention for the preparation of compounds of formula I

wherein R ₁, R₂, R₃, and A are as defined under formula I, W is a W₉group

(W ₉), and R₃₆, R₃₇, X₁₇, and X₁₈are as defined under formula I, corresponding to a compound of formula Ii in reaction scheme 9, is carried out by analogy with known methods, such as those described for example in WO 95/00521, EP-A-0 611 708 and WO 94/25467, and comprises for example reacting

a) a compound of formula VIIIc

b) a compound of formula IXc

wherein the radicals R ₁, R₂, R₃and X₁₈in compounds of formulae VIIIc and IXc have the meanings indicated, if necessary in the presence of a suitable solvent and a base, with a compound of formula XXIX

R₃₇—NH—NH—R₃₆ (XXIX),

wherein R ₃₆and R₃₇are as defined under formula I, and obtaining a compound of formula XXX

and subsequently reacting this, if necessary in a solvent and in the presence of a base, with

a (thio-)carbonylation reagent of formula XXXI

wherein X ₁₇has the meaning indicated, and L₃is a leaving group (reaction scheme 9), and subsequently performing if necessary oxidization

wherein R ₁, R₂, R₃and A are as defined under formula I, W is a W₁₀group

(W ₁₀), and R₃₈, R₃₉, and X₁₉are as defined under formula I, corresponding to a compound of formula Ik in reaction scheme 10, is carried out by analogy with known methods, such as those described for example in U.S. Pat. No. 5,980,480, DE-A-3 917 469, U.S. Pat. Nos. 4,818,275, 5,041,155 und EP-A-0 610 733, and comprises, for example,

a) reacting a compound of formula XIV

if necessary in the presence of a catalyst, with a compound of formula XXXII

to form a compound of formula XXXIII

wherein the radicals R ₁, R₂, R₃and R₃₉in the compounds of formulae XIV, XXXII and XXXIII have the meanings indicated, and further cyclizing this compound with an azide of formula XXXIV

(X ₁₉=, R₃₈=H), or

b) cyclizing a compound of formula XIV

with a compound of formula XXXVI

wherein the radicals R ₁, R₂, R₃and R₃₉in the compounds of formulae XIV and XXXVI have the meanings indicated, (X₁₉=, R₃₈=H), or

c) cyclizing a compound of formula XIV

first with a compound of formula XXXVII

R₃₉—CHO (XXXVII)

to form a compound of XXXIIIa

then with an alkali metal cyanate to form a compound of XXXVIII

and finally cyclizing this compound in the presence of an oxidation agent and obtaining a compound of formula Ik

wherein R ₁, R₂, R₃and R₃₉have the meanings indicated, X₁₉is oxygen, and R₃₈is hydrogen, and treating this compound if necessary with a sulfur reagent (X₁₉=S) and in the presence of a base with an alkylation reagent of formula XXXV

R₃₈—L (XXXV),

wherein R ₃₈is C₁-C₄alkyl, C₁-C₄halogenalkyl, C₃- or C₄alkenyl, C₃- or C₄halogenalkenyl or C₃- or C₄alkinyl, and L is a leaving group, and subsequently performing if necessary oxidization

and thionization.

The method described in the invention for the preparation of compounds of formula I is carried out in a manner analogous to known methods and comprises, for example, reacting a compound of formula III

wherein R ₁, R₂and R₃are as defined under formula I, and L₄is a leaving group, such as halogen, for example fluorine, chlorine or bromine, with a compound of WO,, W₀₂, W₀₃, W₀₄, W₀₅, W₀₆, W₀₇, W₀₈, W₀₉or W₀₁₀

(W ₀₁₀), wherein R₁₅to R₃₉and X₆to X₁₉are as defined under formula I, if necessary in the presence of a suitable solvent and base, and if necessary subjecting the obtainable compounds of formula I (A ═N—) to oxidation

and thionization.

The method described in the invention for the preparation of compounds of formula II

wherein R ₁and R₂are as defined under formula I, W is a

(W ₁₀) group; R₂₁to R₃₀, R₃₆to R₃₉, X₉to X₁₂and X₁₇to X₁₉are as defined under formula I, and L₄is a leaving group, such as halogen for example, especially chlorine or bromine, is carried out in a manner analogous to known methods and comprises, for example, first oxidizing a compound of formula XXXIX

in a suitable solvent to form a compound of formula XXXX

wherein radicals R ₁, R₂and W in the compounds of formulae XXXIX and XXXX have the meanings indicated, and then subjecting the compound either to

a) halogenation, for example with phosphorus oxychloride, if necessary in the presence of a base and a suitable solvent, or

b) transformation in an inert solvent in the presence of an anhydride or antimony pentachloride, and following aqueous treatment, to form a compound of XXXXI

(so-called Katada reaction), and the halogenation of this compound if necessary in the presence of a base and a suitable solvent as described under variant a).

The above methods of preparation are explained in more detail in the following reaction schemes 1 to 12.

The preparation of a compound of formula I

wherein R ₁to R₃, A and W are as defined under formula I, is explained in the following reaction scheme 1:

The pyridine derivatives of formula I, wherein R ₃is a HOOC— or R₅OOC group, may be prepared according to variant a) in reaction scheme 1 in a manner analogous to known methods, a useful method being to react for example the 6-halogen pyridine (L₄=halogen) of formula II in the presence of a palladium or nickel catalyst, such as a palladium triphenylphosphine complex (PdCl₂(PPh₃)₂), with carbon monoxide under pressure in an autoclave, if necessary in the presence of an alcohol of formula V

R₅—OH (V)

and a base, such as a trialkylamine, for example triethylamine.

According to variant b) in reaction scheme 1, pyridine derivatives of formula I, wherein R ₃is a B₁—C₂-C₈alkenyl, B₁—C₂-C₈alkinyl or B₂—C(R₁₂)═CH group, are obtainable in a manner analagous to known methods, such as those described in “Transition Metals in Organic Synthesis”, Editor S. Gibson, Oxford Press, 1997, for example starting from a 6-halogen pyridine of formula II (L₄=halogen) under the conditions of the Heck reaction with an olefin in the presence of a palladium catalyst, such as palladium(II) acetate (Pd(CH₃COO)₂), a tertiary amine, such as triethylamine, and a solvent. According to variant c) in reaction scheme 1, pyridine derivatives of formula I, wherein R₃is a cyano group, are obtainable for example directly by reacting for example the 6-halogen pyridine of formula II (L4 =halogen) with a cyanidation reagent such as an alkali metal cyanide, for example potassium or sodium cyanide, a transition metal cyanide, for example copper cyanide, a tetraalkylammonium cyanide or trialkylsilyl cyanide, for example trimethylsilyl cyanide, in an inert solvent.

According to variant d) in reaction scheme 1, a reactivation for example of the 6-halogen pyridine of formula II (L ₄=halogen) first takes place via oxidation to form the corresponding pyridine-N-oxide of formula IV and the reaction thereof with dimethylcarbamoyl chloride to form the reactive 1-carbamoyloxypyridinium salt. The following reaction of this pyridinium salt with a cyanidation reagen is carried out in a manner analogous to that described under c). Such cyanidation reactions are described for example in Heterocycles 22, 1121 (1984), J.Org.Chem. 48, 1375 (1983) and U.S. Pat. No. 4,776,219.

Further derivatization of the pyridine derivatives of formula I, primarily obtainable according to variants a) to d) in reaction scheme 1, wherein R ₃is a carboxyl, alkoxycarbonyl, alkenyl or alkinyl, or cyano group, and A is nitrogen, can be readily accomplished, taking into account the chemical reactivities of the pyridyl and W parts (groups W₁to W₁₀), in a manner analogous to known standard methods, such as esterification, transesterification, hydrolysis, oxidative or reductive processes, or condensation reactions, for example the Wittig-Horner reaction. Such standard methods are described for example in WO 93/06090, EP-A-0 240 659 and in Houben-Weyl, “Methoden der Organischen Chemie”, Vol. E1, Thieme Verlag Stuttgart, 1982.

The preparation of a compound of formula Ia

wherein R ₁, R₂, R₃, R₁₅, R₁₆, R₁₇, X₆and X₇are as defined under formula I, is explaine the following reaction scheme 2.

For the preparation of the compounds of formula Ia according to the invention, many known standard methods are available, such as those described for example in EP-A-0 438 209 and DE-OS-19 604 229 (R ₁₆=Cyano). In reaction scheme 2, a selection of suitable preparative processes is shown, wherein the choice of reaction pathways and reagents depends on the reactivities of the substituents in the intermediate stages. Starting for example from a compound of formula III, the aminopyridine of formula VI can be obtained by reacting with ammonia in an inert solvent, if necessary in an autoclave at temperatures from −10 to 180° C. This aminopyridine can be reacted in the presence of a base and a solvent either

a) with a chloroformate of formula VII (X ₆=O or S) to form a pyridyl carbamate of formula VII, or

b) with oxalyl chloride, phosgene (X ₆=O) or thiophosgene (X₆=S) to form an iso(thio)cyanate of formula IX. Such reactions are described for example in Angew. 1971, 407. The carbamate and iso(thio)cyanate of formulae VII and IX can be cyclized in the presence of the enamine derivative of formula X in an inert solvent to form the uracil derivative of formula XI, the reaction of the iso(thio)cyanate of formula IX being advantageously carried out in the presence of 0.1-1.5 equivalents of a base, for example sodium hydride, potassium tert-butylate or alkaline earth metal oxide or hydroxide, for example barium hydroxide. The desired compounds of formula Ia can be prepared from the uracils of formula XI, according to standard methods, in the presence of an inert solvent and at least 1 equivalent of a base, for example an alkali metal carbonate such as potassium carbonate,

c) with an alkylation agent of formula XII to form an N-alkyl derivative of formula Ia (R ₁₅=alkyl), or

d) in analogy to WO 97/05116 with a hydroxylamine derivative of formula XII, wherein L ₁is a leaving group such as HOS(O)₂O—

for example 2,4-dinitrophenylhydroxylamine or hydroxylamine-O-sulfonic acid, to form the N-amino derivative of formula Ia (R ₁₅=amino). The desired thiono derivatives of formula Ia (X₆, X₇=S ) can be obtained by thionization, for example with phosphorus pentasulfide or Lawesson's reagent.

The preparation of a compound of formula Ib

wherein R ₁, R₂, R₃, R₁₈, R₁₉, R₂₀, and X₈are as defined under formula I, is explained in the following reaction scheme 3.

Reaction scheme 3:

The compounds of formula Ib can be prepared according to known methods, for example according to reaction scheme 3 (variant a)) by reacting a 2-halogen pyridine derivative of formula IlIl (L4=halogen) with hydrazine, preferably in an amphiprotic solvent, such as alcohols, by analogy with GB-A-2 230 261, to form the 2-hydrazino derivative of formula XIV.

This is reacted with a diketone of formula XV, by analogy with DE OS-1 9754348, or with a dihalogen ketone of formula XVa, by analogy with WO 97/07104, to form the hydrazone derivative of formula XVII. Subsequent cyclization to the desired compound of formula Ib takes place in the presence of the phosphoran derivative of formula XVIII, if necessary in the presence of a base, for example 4-dimethylaminopyridine. If X ₈=O in a compound of formula Ib, then thionization can subsequently be carried out in a manner similar to that described under reaction scheme 2 (X₈=S). According to reaction scheme 3, the hydrazone derivative of formula XVII can also be obtained from the 2-aminopyridine derivative of formula VI by means of diazotization, preferably under exclusion of water, and subsequent coupling with the keto acid of formula XVI (Japp-Klingemann reaction similar to that described under DE-OS-19754348)—(variant b) in reaction scheme 3).

The preparation of a compound of formula Ig

wherein R ₁, R₂, R₃, R₃₁, R₃₂, R₃₃, and X₁₄are as defined under formula I, is explained in the following reaction scheme 4.

Compounds of formula Ig can be prepared in a manner analogous to known methods, as described, for example, in EP-A-0 272 594, EP-A-0 493 323, DE-A-3 643 748, WO 95/23509, U.S. Pat. Nos. 5,665,681 or 5,661,109. For example, according to reaction scheme 4, either

a) a carbamate derivative of formula VIlIla in the presence of a solvent and a base, or

b) an iso(thio-)cyanate of formula IXa, if necessary in a suitable solvent, can be cyclized with an amino acid derivative of formula XIX via a compound of formula XX in the presence of a base and a suitable solvent to form a compound of formula Ig. For those cases (variant c)) where, in a compound of formula Ig, R ₃₃is hydrogen and X₁₃and/or X₁₄are/is oxygen, alkylation can subsequently be carried out, if necessary with an alkylation reagent of formula XXI, on the free N-atom of the hydantoin ring and the ring carbonyl group then thionized (X₁₃and/or X₁₄=S).

The preparation of a compound of formula Ih

wherein R ₁, R₂, R₃, R₃₄, R₃₅, X₁₅, and X₁₆are as defined under formula I, is explained in the following reaction scheme 5.

Compounds of formula Ih can be prepared in a manner analogous to known methods, as described for example in EP-A-0 210 137, DE-OS-2 526 358, EP-A-0 075 267 or EP-A-0 370 955. For example, according to reaction scheme 5, either

a) a carbamate derivative of formula VIIIb in the presence of a solvent and a base, or

b) an iso(thio-)cyanate of formula IXb, if necessary in a suitable solvent, can be cyclized with a carbazate of formula XXII via a compound of formula XXIII in the presence of a base and a suitable solvent to form a compound of formula Ih.

For those cases (variant c)) where, in a compound of formula Ih, R ₃₄and/or R₃₅are/is hydrogen and X₁₅and/or X₁₆are/is oxygen, alkylation can subsequently be carried out with an alkylation reagent of formula XXIVa or XXIVb on the free N-atoms and the ring carbonyl groups then thionized with a thionization reagent (X₁₅and/or X₁₆=S) For the preparation of compounds of formula Ih in reaction scheme 5, wherein R₃₄and R₃₅together form an alkylene bridge which is broken for example by —S(O)₂—, a compound of formula Ih, wherein R₃₄and R₃₅are hydrogen, can be reacted for example with an appropriate Michael acceptor, e.g. CH₂═—CH—S(O)₂CH₃or CH₂═CH—S(O)₂—CH═CH₂, and the resulting Michael addition products then functionalized.

The preparation of a compound of formula Ic

wherein R ₁, R₂, R₃, and R₂₁to R₂₃are as defined under formula I, is explained in the following reaction scheme 6.

According to reaction scheme 6, the pyrazol compounds of formula Ic can be prepared e.g. either from the hydrazinopyridine derivatives of formula XIV by means of condensation with a 1,3-dicarbonyl derivative of formula XXV (variant a)), or by means of condensation with a β-carbonylcarboxylic acid derivative of formula XXVa, where L ₂is a leaving group, such as C₁-C₄alkoxy, hydroxy or halogen, for example chlorine or bromine (variant b)), and subsequent treatment of the resulting pyridylpyrazolone derivative of formula XXVI with a halogenation agent, for example phosphorus oxychloride (R₂₁=halogen). The two reaction steps a) and b) in reaction scheme 6 are carried out if necessary in the presence of an acidic, basic or bifunctional catalyst, such as p-toluenesulfonic acid. The compounds of formula Ic obtained in this way can be further functionalized using standard methods according to the definition of substituents R₂₁to R₂₃. Compounds of formula Ic in reaction scheme 6, wherein R₂₂is hydrogen, can be further functionalized according to the definition of R₂₂, e.g. using an electrophilic reagent, for example a halogenation agent, such as an elementary halogen or sulfurylhalogenide, to form the corresponding compounds of formula Ic, wherein R₂₂is halogen, or using a nitrating agent such as nitric acid in a mixture with a further strong acid, such as sulfuric acid, to form the corresponding compounds of formula Ic, wherein R₂₂is nitro.

The preparation of a compound of formula Id

wherein R ₁, R₂, R₃, and R₂₄to R₂₆are as defined under formula I, is explained in the following reaction scheme 7.

According to reaction scheme 7, the tetrahydroindazol compounds of formula Id can be obtained by known methods from the hydrazinopyridine derivatives of formula XIV, for example either by means of condensation with a cyclohexanone derivative of formula XXVb acylated in the 2-position, wherein R ₂₄is as defined under formula I, except where R₂₄is halogen or cyano (variant a)), or by means of condensation with a cyclohexanone derivative of formula XXVc, wherein L₂is a leaving group, such as C₁-C₄alkoxy, hydroxy or halogen, for example chlorine or bromine, and subsequent halogenation (variant b)) in a manner analogous to that described under reaction scheme 6.

The halogen derivatives of formula Id, wherein R ₂₄is halogen, can be reacted according to known methods with an alkali metal, ammonium or metal cyanide, wherein the metal ion is selected from the first or second subgroup of the periodic system, if necessary with the addition of an alkali metal iodide, to form the corresponding cyano-substituted derivatives pf formula Id (R₂₄=CN).

The preparation of compounds of formulae Ie and If

wherein R ₁, R₂, R₃, R₂₇to R₃₀and X₉to X₁₂are as defined under formula I, is explained in the following reaction scheme 8.

According to reaction scheme 8, the pyrrolindione derivatives of formula Ie and the tetrahydroisoindolindione derivatives of formula If can be obtained in a manner analogous to known methods, for example by reacting an anhydride of formula XXVIII (variant a)) and/or XXVIIla (variant b)) with an aminopyridine of formula VI in an inert solvent, such as ether, for example dioxan, or a lower alkylcarboxylic acid, for example propionic acid, at temperatures of 20-200° C. The compounds of formulae Ie and If (X ₉to X₁₂=O) which are obtainable according to reaction scheme 8 can be thionized if necessary with a suitable sulfur reagent (X₉to X₁₂=S).

The preparation of a compound of formula Ii

wherein R ₁, R₂, R₃, R₃₆, R₃₇, X₁₇, and X:₈are as defined under formula I, is explained following reaction scheme 9.

According to reaction scheme 9, compounds of formula Ii can be prepared by known methods, for example by first reacting a carbamate of formula VIIIc (variant a)) and/or an isothiocyanate of formula IXc (variant b)) with a hydrazine derivative of formula XXIX to form the semicarbazide derivative of formula XXX, and then cyclizing this derivative in the presence of a carbonylation or thiocarbonylation reagent of formula XXXI. Both reaction steps are usefully accomplished in a suitable solvent and in the presence of a base. A suitable (thio)carbonylation reagent of formula XXXI is for example phosgene, diphosgene, thiophosgene or carbonyidiimidazol. L ₃in a compound of formula XXXI is therefore a leaving group such as a halogen, for example, chlorine or bromine, trichloromethoxy or

The preparation of a compound of formula Ik

wherein R ₁, R₂, R₃, R₃₈, R₃₉, and X₁₉are as defined under formula I, is explained in the following reaction scheme 10.

According to reaction scheme 10, the triazolone derivatives of formula Ik can be prepared in a manner analogous to known methods, starting for example from the hydrazinopyridine derivative of formula XIV, which according to variant a) is usefully reacted with a keto acid of formula XXXII in the presence of an acid catalyst, such as a lower alkylcarboxylic acid, for example propionic acid, a mineral acid, for example sulfuric acid or hydrochloric acid, or a sulfonic acid, for example p-toluenesulfonic acid, to form a hydrazone derivative of formula XXXIII. This can subsequently be cyclized with an azide of formula XXXIV to form a triazolone derivative of formula Ik, wherein X ₁₉is oxygen, and R₃₈is hydrogen, and then further derivatized if necessary according to standard methods using an alkylation reagent of formula XXXV or a sulfur reagent. According to variant b), the hydrazinopyridine derivative of formula XIV can be cyclized with an iminoether of formula XXXVI to form a triazolone derivative of formula Ik, wherein X₁₉is oxygen, and R₃₈is hydrogen, and then if necessary alkylated or thionized as described under variant a). According to variant c) in reaction scheme 10, the hydrazinopyridine derivative of formula XIV can be reacted first with an aldehyde of formula XXXVII and then, in the presence of a lower alkylcarboxylic acid, such as acetic acid, with an alkali metal cyanate to form a compound of formula XXXVIII which, if necessary, is not isolated, and finally cyclized with an oxidizing agent, such as alkali metal hypochlorite (Javelle) to form a compound of formula Ik, wherein X₁₉is oxygen, and R₃₈is hydrogen. If necessary, the resulting compound of formula Ik can be alkylated or thionized, as described under variant a).

In certain cases, compounds of formula I can also be usefully obtained in a manner analogous to that described in J. Het. Chem. 15, 1221 (1978) by the substitution of a 2-halogen pyridine of formula IlI (L ₄=halogen), if necessary in the presence of a suitable solvent and a base, with the desired heterocycles of formulae W₀₁to W₀₁₀

or alkali metal salts thereof, as illustrated with the example of a compound of formula Ic in reaction scheme 11.

The intermediate products of formula II

wherein R ₁and R₂are as defined under formula I, L₄is a leaving group, such as halogen or C₁-C₄alkyl or phenylsulfonyl, and W is a W₃, W₄, W₅, W₆, W₉or W₁₀group, are new. The invention thus also relates to these compounds.

The preparation of compounds of formula 11 is explained in reaction scheme 12.

The pyridin-N-oxides of formula XXXX (reaction scheme 12) can be prepared according to known methods, such as described in Org. Synth. 4, 828 (1963); ibid. 3, 619 (1955); U.S. Pat. No. 3,047,579; and B. Iddon and H. Suschitzky in “Polychloroaromatic Compounds”, Editor H. Suschitzky, Plenum Press, London 1974, page 197, a useful method being to react the pyridine derivatives of formula XXXIX with oxidizing agents, such as organic peroxy acids, for example m-chloroperbenzoic acid, peracetic acid and pertrifluoracetic acid, or aqueous hydrogen peroxide solution or hydrogen peroxide urea adduct together with carboxylic acids and/or carboxylic acid anhydrides, or inorganic peroxy acids, for example peroxymonosulfuric acid (Caro's acid). Suitable solvents are, for example, water, organic acids such as acetic acid and trifluoracetic acid, halogenated hydrocarbons such as dichloromethane and 1,2-dichloroethane, esters such as ethyl acetate, ethers such as tetrahydrofuran and dioxan or mixtures comprising these solvents. The reaction temperatures lie within the range of −20° C. to 100° C., depending on the solvent or solvent mixture used. The pyridin-N-oxides of formula XXXX can be halogenated either directly according to known methods, for example with phosphorus oxychloride, phosphorus oxybromide, sulfuryl chloride, thionyl chloride or phosphorus pentachloride in phosphorus oxychloride to form the halogen pyridine derivatives of formula II (L ₄=halogen), or first reacted—likewise according to known methods (e.g. Quart. Rev. 10, 395 (1956); J. Am. Chem. Soc. 85, 958 (1963); and J. Org. Chem. 26, 428 (1961))—in the presence of anhydrides, for example acetic anhydride, trifluoracetic anhydride and methanesulfonic acid anhydride in a suitable inert solvent, such as halogenated hydrocarbons, for example dichloromethane and 1,2-dichloroethane, amides such as N,N-dimethylformamide and 1 -methyl-2-pyrrolidone and if necessary in the presence of sodium acetate, to form the pyridol derivatives of formula XXXXI, which can then then be halogenated to form halogen pyridines of formula II, as described above for compounds of formula XXXX (L₄=halogen).

The reaction temperatures for this transformation reaction generally lie within the range of −30° C. to 80° C. By analogy with Tetrahedron 37, 187 (1981), antimony pentachloride (Katada reaction) presents itself as a further variant for the above transformation reaction.

wherein R ₁and R₂are as defined under formula I, W is a W₁to W₁₀group, and L₄is a C₁-C₄alkyl or phenylsulfonyl group, is carried out starting from a compound of formula II, wherein R₁, R₂and W have the meanings indicated and L₄is halogen, by means of reaction with a C₁-C₄alkyl or phenyl thiol in the presence of a suitable base, followed by oxidation of the resulting thioether with an oxidizing agent such as hydrogen peroxide or m-chloroperbenzoic acid. The starting compounds of formula XXXIX used in reaction scheme 12 can be prepared in a manner analogous to the methods described for compounds of formula Ia to Ik (R₃=hydrogen) under reaction schemes 2 to 11.

The compounds of formulae III and VI are known or can be prepared according to known methods, as described in DE-A-3 917 469; WO 97/07114; WO 92/00976; JP-A-58-213 776; EP-A-0 012 117; EP-A-0 306 547; EP-A-0 030 215; EP-A-0 272 824; EP-A-0 500 209; U.S. Pat. Nos. 4,996,323; 5,017,705; WO 97/05112; J. Het. Chem. 11, 889 (1974); J. Het. Chem 21, 97 (1984); Tetrahedron 41, 4057 (1985); Heterocycles 22, 117; Synth. 1988, 938; J. Med. Chem. 25, 96. The 2-aminopyridines of formula VI can in addition be prepared by Curtius, Hofmann or Lossen reactions from corresponding pyridine derivatives with carboxylic acid, carboxylic acid chloride, carboxylic acid azide, carboxylic acid ester or carboxylic acid amide functions in Position 2.

The reagents of formulae V, VII, X, XII, XIII, XV, XVa, XVI, XVIII, XIX, XXI, XXII, XXIVa, XXIVb, XXV, XXVa, XXVb, XXVc, XXXIV, XXVIII, XXVIIIa, XXIX, XXXI, XXXII, XXXIV, XXXV, XXXVI and XXXVII as used in reaction schemes 1 to 10 are either known or can be prepared in a manner analogous to disclosed methods.

The heterocycles of formulae W ₀₁to W₀₁₀are either known or can be prepared in a manner analogous to known standard methods of heterocyclic chemistry.

The reactions for obtaining the compounds of formula I are advantageously carried out in aprotic inert organic solvents. Such solvents are hydrocarbons such as benzene, toluene, xylene or cyclohexane, chlorinated hydrocarbons such as dichloromethane, trichloromethane, tetrachloromethane or chlorobenzene, ethers, including diethyl ether, 1,2-dimethoxyethane, diglyme, tetrahydrofuran or dioxane, nitriles such as acetonitrile or propionitrile, amides such as N,N-dimethyl formamide, diethyl formamide or N-methyl-pyrrolidinone. The reaction temperatures are preferably in the range from −20° to +120° C. The reactions are usually slightly exothermic and can as a rule be carried out at room temperature. The reaction mixture can be heated for a brief time to boiling point to shorten the reaction time or also to initiate the reaction. The reaction times can also be shortened by addition of a few drops of a base as reaction catalyst. Particularly suitable bases are tertiary amines such as trimethylamine, triethylamine, quinuclidine, 1,4-diazabicyclo[2.2.2]octane, 1,5-diazabicyclo[4.3.0]non-5-ene or 1,5-diazabicyclo[5.4.0]undec-7-ene. Further suitable bases are also inorganic bases, typically hydrides such as sodium or calcium hydride, hydroxides such as sodium and potassium hydroxide, carbonates such as sodium and potassium carbonate, or hydrogencarbonates such as potassium and sodium hydrogencarbonate. The compounds of formula I can be isolated in conventional manner by concentrating the reaction mixture and/or removing the solvent by evaporation and by recrystallizing or triturating the solid residue in a solvent in which it is not readily soluble, typically an ether, an aromatic hydrocarbon or a chlorinated hydrocarbon, or by means of column chromatography and a suitable eluent.

The compounds of formula I or compositions containing them may be used according to this invention by all standard methods of application used in agriculture, including preemergence application, postemergence application and seed dressing, as well as by different methods and techniques such as controlled release. For controlled release, a solution of the herbicide is applied to mineral granular carriers or to polymerized granules (urea/formaldehyde) and then dried. A coating can then be additionally applied (coated granules) that allows the herbicide to be released at a controlled rate over a specific period of time. The compounds of formula I may be used as herbicides in unmodified form, i.e. as obtained in the synthesis. Preferably they are processed in conventional manner with the auxiliary agents customarily employed in formulation technology, e.g. to emulsifiable concentrates, directly sprayable or dilutable solutions, dilute emulsions, wettable powders, soluble powders, dusts, granulates or microcapsules. Such formulations are described, for example, in WO 97/34485 on pages 9 to 13. As with the type of agents, the methods of application such as spraying, atomizing, dusting, wetting, scattering or pouring, are selected in accordance with the intended objectives and the prevailing circumstances. The formulations, i.e. the agents, preparations, or compositions containing the compound of formula I or at least one compound of formula I and usually one or more than one liquid or solid formulation assistant, are prepared in known manner, e.g. by homogeneously mixing and/or grinding the herbicide with said formulation auxiliaries, typically solvents or solid carriers. Surface-active compounds (surfactants) may additionally be used for preparing the formulations. Examples of solvents and solid carriers are described in WO 97/34485 on page 6. Depending on the herbicide of formula I to be formulated, suitable surface-active compounds are nonionic, cationic and/or anionic surfactants and surfactant mixtures having good emulsifying, dispersing and wetting properties. Examples of suitable anionic, non-ionic, and cationic surfactants are listed in WO 97/34485 on pages 7 and 8. Also the surfactants customarily employed in the art of formulation and described, inter alia, in “McCutcheon's Detergents and Emulsifiers Annual” MC Publishing Corp., Ridgewood N.J., 1981, Stache, H., “Tensid-Taschenbuch” (Handbook of Surfactants), Carl Hanser Verlag, Munich/Vienna, 1981, and M. and J. Ash, “Encyclopedia of Surfactants”, Vol I-III, Chemical Publishing Co., New York, 1980-81 are suitable for manufacture of the herbicides according to the invention.

The herbicidal compositions will as a rule contain from 0.1 to 99% by weight, preferably from 0.1 to 95% by weight, of herbicide, from 1 to 99.9% by weight, preferably from 5 to 99.8% by weight, of a solid or liquid adjuvant, and from 0 to 25% by weight, preferably from 0.1 to 25% by weight, of a surfactant. Whereas it is preferred to formulate commercial products as concentrates, the end user will normally use dilute formulations. The compositions may also contain further ingredients, such as: stabilisers, e.g. where appropriate epoxidized vegetable oils (epoxidized coconut oil, rapeseed oil, or soybean oil); antifoams, typically silicone oil; preservatives; viscosity regulators; binders; and tackifiers; as well as fertilizers or other chemical agents. The compounds of formula I are usually applied with success to the plants or the locus thereof in concentrations of 0.001 to 4 kg/ha, especially 0.005 to 2 kg/ha. The concentration required to achieve the desired action can be determined by experimentation. It will depend on the type of action, the development stage of the cultivated plant and of the weed, as well as on the application (locus, time, method), and as a result of these variables can vary over a wide range. The compounds of formula I have excellent herbicidal and growth inhibiting properties, which make them suitable for application in crops of cultivated plants, especially in cereals, cotton, soybeans, sugar beet, sugar cane, plantations, rape, maize, and rice, and for the non-selective control of weeds. Crops will also be understood as meaning those crops that have been made tolerant to herbicides or classes of herbicides by conventional breeding or genetic engineering methods. The weeds to be controlled may be monocot as well as dicot weeds, typically Stellaria, Nasturtium, Agrostis, Digitaria, Avena, Setaria, Sinapis, Lolium, Solanum, Echinochloa, Scirpus, Monochoria, Sagittaria, Bromus, Alopecurus, Sorghum halepense, Rottboellia, Cyperus, Abutilon, Sida, Xanthium, Amaranthus, Chenopodium, Ipomoea, Chrysanthemum, Galium, Viola, and Veronica.

The invention is illustrated by the following non-limitative Examples.

PREPARATIVE EXAMPLES

Example H1

Preparation of 2-N-ethoxicarbonylamino-3-fluoro-5-chloropyridine

[0270]
294 g 2-Amino-3-fluoro-5-chloropyridine is dissolved in 1 l dry pyridine and cooled to 0° C., then 220 g ethyl chloroformate is stirred in drop by drop and stirring continued at 22° C. until the reaction is complete. The reaction mixture is then poured onto ice water, adjusted to pH 4-5 with 2N hydrochloric acid and extracted with ethyl acetate. The combined extracts are washed with water, dried over sodium sulfate, concentrated by evaporation and crystallized by the addition of n-hexane. The precipitate obtained is filtered off, washed with n-hexane and dried in a vacuum. The title compound is obtained with a melting point of 132° C. [0271]

Example H2

Preparation of 1-(3-fluoro-5-chloropyridin-2-yl)-3-methyl-4-trifluoromethylpyrimidin-2,6-dione

[0272]
Under a nitrogen atmosphere, while cooling and stirring, a solution of 22.7 g 4,4,4-trifluoro-3-amino-2-butenoic acid ethyl ester is added dropwise to 5.1 g of a sodium hydride dispersion (60%) in 60 ml N-methylpyrrolidine at 0-5° C. and stirred at 22° C. until hydrogen evolution is complete. Then 23.7 g 2-ethoxicarbonylamino-3-fluoro-5-chloropyridine (Example H1) is added and the reaction mixture heated for about 5 hours to 120° C. The mixture is then cooled, 16.7 g methyl iodide is added dropwise and stirring is continued overnight at 22° C. After the reaction mixture has been taken up in ethyl acetate, it is washed with ice water, dried over sodium sulfate, filtered, and concentrated by evaporation. The residue obtained is recrystallized from ethyl acetate/n-hexane. The title compound is obtained with a melting point of 133-134° C. [0273]

Example H3

Preparation of 1-(3-fluoro-5-chloro-2-pyridyl-N-oxide)-3-methyl-4-trifluoromethylpyrimidin-2,6-dione

[0274]
24 g 1-(3-Fluoro-5-chloropyridin-2-yl)-3-methyl-4-trifluoromethylpyrimidin-2,6-dione (Example H2) in 150 ml dichloromethane is cooled to −5° C., and 2 g hydrogen peroxide-urea adduct is added. Then 2.7 ml trifluoracetic acid anhydride, dissolved in 2 ml dichloromethane, is added dropwise and the reaction mixture is stirred overnight after the exothermic reaction has subsided. Within 3 hours another 5 g of hydrogen peroxide-urea adduct and 3 ml trifluoracetic acid anhydride are added in 2 portions and, after the exothermic reaction has subsided, the mixture is heated to 25-350° C. until the reaction is complete. The mixture is then cooled and, at −5° C., is adjusted to pH 7.5 first with 2N sodium hydroxide solution, then with saturated sodium hydrogencarbonate solution, distributed between dichloromethane and ice water, and the separated organic phase dried over sodium sulfate, filtered and concentrated by evaporation. The remaining solid residue is recrystallized from ethyl acetate/n-hexane. The desired title compound is obtained with a melting point of 142-143° C. [0275]

Example H4

Preparation of 1-(3-fluoro-5,6-dichloro-2-pyridyl)-3-methyl-4-trifluoromethylpyrimidin-2,6-dione

[0276]
To a solution of 2.4 ml phosphorus oxytrichloride in 20 ml 1,2-dichloroethane, heated to 70° C., portions of 6.8 g 1-(3-fluoro-5-chloro-2-pyridyl-N-oxide)-3-methyl-4-trifluoromethylpyrimidin-2,6-dione (Example H3) are added, maintained at this temperature overnight, before a further 4.0 ml phosphorus oxytrichloride is added and heated for 20 hours. The mixture is then cooled, poured over ice water, extracted with dichloroethane, and the combined extracts are washed with 2N sodium hydroxide solution and water, dried over sodium sulfate and evaporated by concentration. The residue is purified by means of silica gel chromatography (eluent: hexane/ethyl acetate 9/1). The title compound is obtained with a melting point of 113-115° C. [0277]

Example H5

Preparation of 1-(2-hydroxy-3-chloro-5-fluoropyridin-6-yl)-3-methyl-4-trifluoromethylpyrimidin-2,6-dione and 1-(3-hydroxy-2-chloro-5-fluoropyridin-6-yl)-3-methyl-4-trifluoromethylpyrimidin-2,6-dione

[0278]
To a solution of 29.6 g 1-(3-fluoro-5-chloro-2-pyridyl-N-oxide)-3-methyl-4-trifluoromethylpyrimidin-2,6-dione (Example H3) in 400 ml dimethylformamide, cooled to −30° C., 182 g trifluoracetic acid anhydride is added dropwise, and the mixture is then stirred overnight at −30° C., and on the next day at 22° C. In a vacuum, the mixture is then liberated from surplus trifluoracetic acid anhydride, cooled to −5° C. and carefully neutralized first with diluted sodium hydroxide solution and then with sodium hydrogencarbonate solution. After the addition of ice water, the mixture is extracted with ethyl acetate, and the combined extracts are washed with water and dried over sodium sulfate. This is then filtered, the filtrate concentrated by evaporation and the resulting residue purified over a silica gel column (eluent: n-hexane/ethyl acetate 8/2) with an ascending gradient in respect of ethyl acetate. The title compound is obtained with a melting point of 200-202° C. In addition, a fraction is obtained which, besides 1-(2-hydroxy-3-chloro-5-fluoropyridin-6-yl)-3-methyl-4-trifluoromethylpyrimidin-2,6-dione, comprises also the isomer 1-(3-hydroxy-2-chloro-5-fluoropyridin-6-yl)-3-methyl-4-trifluoromethylpyrimidin-2,6-dione. The latter isomeric compound is obtained by a further rearrangement reaction. The ratio of the two isomers 1-(2-hydroxy-3-chloro-5-fluoropyridin-6-yl)-3-methyl-4-trifluoromethylpyrimidin-2,6-dione and 1-(3-hydroxy-2-chloro-5-fluoropyridin-6-yl)-3-methyl-4-trifluoromethylpyrimidin-2,6-dione varies (at approx. 3:1) depending on reaction conditions. The isomeric mixture of the fraction can either be used directly for the next reaction step or separated by means of HPLC (Li-Chrospher Si60; eluent: ethyl acetate/hexane 15/85 to 30/70, ascending gradient of ethyl acetate). Pure 1-(3-hydroxy-2-chloro-5-fluoropyridin-6-yl)-3-methyl-4-trifluoromethylpyrimidin-2,6-dione is obtained with a melting point of 189-192° C. [0279]

Example H6

Preparation of 1-(6-Ethoxicarbonyl-5-chloro-3-fluoropyridin-2-yl)-3-methyl-4-trifluoromethylpyrimidin-2,6-dione

[0280]
A mixture of 4 g 1-(3-fluoro-5,6-dichloro-2-pyridyl)-3-methyl-4-trifluoromethylpyrimidin-2,6-dione (Example H4), 3.4 g triethylamine and 2 g dichloro-bis(triphenylphosphine)palladium in 50 ml ethanol is pressurized in an autoclave with carbon monoxide at 180 bar and the mixture heated for about 30 hours to 101° C., leading to a pressure build-up of max. 228 bar. The heating is then switched off, the reaction mixture left to stand at 22° C. over the weekend and filtered; the filtrate is then concentrated by evaporation in a vacuum, and the residue obtained is purified over a silica gel column (eluent: n-hexane/ethyl acetate 9/1). The desired title compound is obtained as a yellowish resin. [0281]

Example H7

Preparation of 1-(2-trifluoromethyl-3-chloro-5-fluoropyridin-6-yl)-3-methyl-4-trifluoromethylpyrimidin-2,6-dione

[0282]
To a solution of 0.848 g of a mixture of 2-hydroxy-3-chloro-5-fluoropyridin-6-yl)-3-methyl-4-trifluoromethylpyrimidin-2,6-dione and 3-hydroxy-2-chloro-5-fluoropyridin-6-yl)-3-methyl-4-trifluoromethylpyrimidin-2,6-dione (Example H5), 0.938 g triphenylphosphine, 0.22 ml 2,2,2-trifluoroethanol and 0.58 ml diethylazodicarboxylate are added at 22° C., and the mixture is stirred for 14 hours at 22° C. The same quantities of triphenylphosphine, diethylazodicarboxylate and trifluoroethanol are added and the mixture is stirred for a further 4 hours. Ice water is then added, distributed between dichloromethane and water, the extracts washed with water, dried and concentrated by evaporation. The residue is first filtered via silica gel (hexane/ethyl acetate 2/1) and then separated by means of HPLC (Li-chrospher Si 60; hexane-ethyl acetate 15-30%, ascending gradient). After the separation of 1-(2-trifluoroethoxy-3-chloro-5-fluoro-6-pyridyl)-3-methyl-4-trifluoromethylpyrimidin-2,6-dione and 1-(3-trifluoroethoxy-2-chloro-5-fluoro-6-pyridyl)-3-methyl-4-trifluoromethylpyrimidin-2,6-dione, the desired title compound is obtained with a melting point of 112-113° C. By analogy, these and analogous trifluoromethyl compounds are obtainable as described in JP-A-58 206 563 or by the reaction of corresponding carboxylic acid derivatives with sulfur tetrafluoride or by the reaction of corresponding trichloromethyl compounds with hydrogen fluoride. [0283]

Example H8

Preparation of tetrahydroimidazol[1,5-a]pyridin-1,3-dione

[0284]
A reaction vessel containing 260 ml water is prepared with 34.6 g (0.193 mol) 2-piperidine-carboxylic acid methyl ester.hydrochloride, to which 17.4 g (0.216 mol) potassium cyanate is then added. Then 30 ml glacial acetic acid is added and the resulting homogeneous solution is stirred for 4.5 hours at 22° C. The reaction solution is subsequently saturated with saline (NaCl) and extracted twice with 200 ml tert-butyl methyl ether each time. The organic fractions are combined, dried over sodium sulfate and concentrated. As residue, 11 g of a viscous oil is obtained, from which crystals precipitate out overnight. Decanting off the remaining oil enables the crystals to be separated off and isolated by trituration (digestion) in diethyl ether. The desired title compound is obtained with a melting point of 122-123° C. in a yield of 5.75 g. [0285]

Example H9

Preparation of 2-(3-fluoro-6-chloro-5-cyano-2-pyridyl)tetrahydroimidazo[1,5-a]pyridin-1,3-dione

[0286]
A reaction vessel is prepared with 0.77 g (0.005 mol) of the hydantoin derivative from Example H8 in 50 ml acetonitrile. To this solution, 0.95 g (0.00688 mol) finely pulverized potassium carbonate and 0.96 g (0.00503 mol) 2,6-dichloro-3-cyano-4-fluoropyridine are added consecutively, and the mixture is stirred and heated to reflux temperature for 5 hours. At the end of this time, no further starting compound is detectable (TLC analysis). The reaction mixture is cooled, filtered, and the solvent evaporated off. The dark brown, viscous oil obtained is chromatographed under pressure over a silica gel column (30 g) (eluent: hexane/ethyl acetate 2/1). The fractions comprising product with an R[0287] _fvalue of 0.26 are combined and liberated from the solvent. The desired product is obtained as white crystals with a melting point of 192-193° C. MS (FD): [M⁺, 40%] 308.

Example H10

Preparation of 2-(5-chloro-3-fluoropyridin-2-yl)-7-hydroxytetrahydroimidazo-(1.5-a)-pyridin-1,3-dione

[0288]
A reaction mixture comprising 100 ml dioxan, 50 ml N,N-dimethylformamide, 8 ml propylene oxide, 6 ml 1.8-diazabicyclo-(5.4.0)-undec-7-en and 8.0 g 4-hydroxypiperidine-2-carboxylic acid ethyl ester.hydrochloride is stirred overnight at 20° C. Then 4.4 g potassium tert-butylate and 50 ml N,N-dimethylformamide are added and the resulting suspension is heated for about 4 hours to 95° C. The reaction mixture is then cooled, adjusted to pH 6.5-7.0 with cold, aqueous 2N hydrochloric acid solution and extracted with ehyl acetate. The combined extracts are washed with saline solution and water, concentrated by evaporation and the solid residue purified by means of silica gel chromatography (eluent: hexane/ethyl acetate). The title compound is obtained as a mixture of two separable diastereomers with a melting point of 183-185° ° C. and 184-186° C. [0289]

Example H 11

Preparation of 2-(5-Chloro-3-fluoro-pyridine-2-yl)-7-fluoro-tetrahydroimidazo-(1.5-a)-pyridine-1,3-dione

2.6 g of 2-(5-Chloro-3-fluoro-pyridine-2-yl)-7-hydroxi-tetrahydroimidazo-(1.5-a)-pyridine-1,3-dione (isomer B) in 80 ml dichlorromethane is treated at −55° C.-−65° C. with 1.9 ml of diethylaminosulfur trifluoride (DAST) and stirred at the same temperature for 1 hr. The vessel is then allowed to stirr at room temperature over night. The resulting brownish solution is treated with ice and water and extracted with ethyl acetate. The extracts are washed with water, dried, filtered through a small siligcagel column and evaporated to give the desired product with m.p. 154-157° C. [0290]

Example H12

Preparation of 2-(6-ethoxycarbonyl-5-chloro-3-fluoro-pyridin-2-yl)-5-trifluoromethyl-2.H.-pyridazin-3-one (compound 35.004)

A mixture of 1.7 g 2-(5,6-dichloro-3-fluoropyridin-2yl)-5-trifluoromethyl-2.H.-pyridazin-3-one, 1 g of bis-(triphenylphosphine)-palladium(II)-dichloride, and 2.3 ml triethylamine in 35 ml ethanol was placed in an autoclave and heated under a pressure of 180-235 bar of carbon monoxide at 100° C. for 24 hrs. Then, the reaction mixture was cooled down, filtered end evaporated. Purification of the residue by HPLC-chromatography (ethyl acetate-hexane) led to the desired product. [0291] ¹H-NMR (CDCl₃): 8.11 ppm (s, 1H); 7.80 ppm (d,1H); 7.35 ppm (s, 1H); 4.46 ppm (q, 2H); 1.41 ppm (t, 3H).
In an analogous manner, 2-(6-ethoxycarbonyl-5-chloro-3-fluoro-pyridin-2-yl)-4-methyl-5-trifluoromethyl-2.H.-pyridazin-3-one (39.004) was obtained. [0292]

Example H13

Preparation of 2-(5.6-dichloro-3-fluoro-pyridin)-2-yl-4-methyl-5-trifluoromethyl-2.H.-pyridazine-3-one

A mixture of 1.6 g 2-(5-chloro-3-fluoro-1-oxy-pyridin-2-yl)-4-methyl-5-trifluoromethyl-2H-pyridazin-3-one and 2 ml of phenyl dichlorophosphate was heated in a sealed tube at 140° C. for 3 hrs. The reaction was then cooled, poured into ice and water, neutralised with aqueous sodium hydrogen carbonate, extracted with ethyl acetate, washed with water and dried over sodium sulfate. After dilution with hexane, the extract was filtered through silicagel and evaporated to give the desired product with m.p. 96-98° C. [0293]

Example H14

Preparation of 2-(5-chloro-3-fluoro-1-oxy-pyridin-2-yl)-4-methyl-5-trifluoromethyl-2H-pyridazin-3-one (compound 625.001)

5.01 g of 2-(5-chloro-3-fluoro-pyridin-2-yl)-4-methyl-5-trifluoromethyl-2H-pyridazin-3-one in 150 ml of 1,2-dichloroethane was treated at 0° C. with 2.1 g hydrogen peroxide-urea adduct and 2.7 ml of trifluoroacetic anhydride and allowed to stir at 20° C. until conversion was complete. Then the solution was poured into ice and water, neutralised with aqueous sodium hydrogen carbonate and extracted with dichloromethane. The extracts were combined, washed with water, dried, filtered and evaporated to give the desired product with m.p. 140-143° C. [0294]

Example H15

Preparation of 2-(5-chloro-3-fluoro-pyridin-2-yl)-4-methyl-5-trifluoromethyl-2H-pyridazin-3-one (608.001)

A solution of 8.09 g 3((5-chloro-3-fluoro-pyridine-2-yl) -hydrazono)-1,1,1-trifluoro-propan-2-one and 11.5 g 1-carbomethoxyethylidene triphenylphosphine in 200 ml dioxane was stired for 30 min. at 20° C. and then heated until complete conversion at 50° C. The reaction mixture was diluted with hexane, filtered from solid triphenylphosphine oxide through silicagel and evaporated. Further purification of the residue on silicagel (ethyl acetate-hexane 3:7) led to the desired product with m.p. 91-93° C. [0295]

Example H16

Preparation of 3-((5-chloro-3-fluoro-pyridin-2-yl)-hydrazono)-1,1,1-trifluoro-propan-2-one (intermediate)

6.75 g 1,1-dibromo-3,3,3-trifluoroacetone were stirred for 30 min. at 80° C. in a solution of 9.0 g sodium acetate in 250 ml water. Then the solution was cooled at 0° C. and 4.0 g 2-hydrazino-3-fluoro-5-chloropyridin were added. Stirring was continued for 3.5 hrs. Then the reaction mixture was extracted with ethyl acetate, the extracts were washed with water and dried. After evaporation, the remaining residue was purified on silcagel (hexane-ethyl acetate 8:2) to give the title compound as brownish residue which was directly used for the next step. MS: (M−H )−=268. [0296]
In analogous manner, 3-((6-chloro-5-cyano-3-fluoro-pyridin-2-yl) -hydrazono)-1,1,1-trifluoro-propan-2-one with m.p. 174-176° C. was obtained. [0297]
The preferred compounds listed in the following tables can also be obtained in an analogous manner and according to the methods illustrated in the general reaction schemes 1-11 and described in the cited references. [0298]
Table 1: A preferred group of compounds of formula I corresponds to the general formula [0299]
wherein substituents R[0300] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁.
Table 2: A further preferred group of compounds of formula I corresponds to the general formula [0301]
wherein substituents R[0302] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₂.
Table 3: A further preferred group of compounds of formula I corresponds to the general formula [0303]
wherein substituents R[0304] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₃.
Table 4: A further preferred group of compounds of formula I corresponds to the general formula [0305]
wherein substituents R[0306] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₄.
Table 5: A further preferred group of compounds of formula I corresponds to the general formula [0307]
wherein substituents R[0308] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₅.
Table 6: A further preferred group of compounds of formula I corresponds to the general formula [0309]
wherein substituents R[0310] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₆.
Table 7: A further preferred group of compounds of formula I corresponds to the general formula [0311]
wherein substituents R[0312] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₇.
Table 8: A further preferred group of compounds of formula I corresponds to the general formula [0313]
wherein substituents R[0314] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₈.
Table 9: A further preferred group of compounds of formula I corresponds to the general formula [0315]
wherein substituents R[0316] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₉.
Table 10: A further preferred group of compounds of formula I corresponds to the general formula [0317]
wherein substituents R[0318] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₀.
Table 11: A further preferred group of compounds of formula I corresponds to the general formula [0319]
wherein substituents R[0320] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₁.
Table 12: A further preferred group of compounds of formula I corresponds to the general formula [0321]
wherein substituents R[0322] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₂.
Table 13: A further preferred group of compounds of formula I corresponds to the general formula [0323]
wherein substituents R[0324] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₃.
Table 14: A further preferred group of compounds of formula I corresponds to the general formula [0325]
wherein substituents R[0326] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₄.
Table 15: A further preferred group of compounds of formula I corresponds to the general formula [0327]
wherein substituents R[0328] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₅.
Table 16: A further preferred group of compounds of formula I corresponds to the general formula [0329]
wherein substituents R[0330] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₆.
Table 17: A further preferred group of compounds of formula I corresponds to the general formula [0331]
wherein substituents R[0332] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₇.
Table 18: A further preferred group of compounds of formula I corresponds to the general formula [0333]
wherein substituents R[0334] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₈.
Table 19: A further preferred group of compounds of formula I corresponds to the general formula [0335]
wherein substituents R[0336] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₉.
Table 20: A further preferred group of compounds of formula I corresponds to the general formula [0337]
wherein substituents R[0338] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₂₀.
Table 21: A further preferred group of compounds of formula I corresponds to the general formula [0339]
wherein substituents R[0340] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₂₁.
Table 22: A further preferred group of compounds of formula I corresponds to the general formula [0341]
wherein substituents R[0342] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₂₂.
Table 23: A further preferred group of compounds of formula I corresponds to the general formula [0343]
wherein substituents R[0344] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₂₃.
Table 24: A further preferred group of compounds of formula I corresponds to the general formula [0345]
wherein substituents R[0346] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₂₄.
Table 25: A further preferred group of compounds of formula I corresponds to the general formula [0347]
wherein substituents R[0348] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₂₅.
Table 26: A further preferred group of compounds of formula I corresponds to the general formula [0349]
wherein substituents R[0350] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₂₆.
Table 27: A further preferred group of compounds of formula I corresponds to the general formula [0351]
wherein substituents R[0352] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₂₇.
Table 28: A further preferred group of compounds of formula I corresponds to the general formula [0353]
wherein substituents R[0354] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₂₈.
Table 29: A further preferred group of compounds of formula I corresponds to the general formula [0355]
wherein substituents R[0356] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₂₉.
Table 30: A further preferred group of compounds of formula I corresponds to the general formula [0357]
wherein substituents R[0358] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₃₀.
Table 31: A further preferred group of compounds of formula [0359]
wherein substituents R[0360] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₃₁.
Table 32: A further preferred group of compounds of formula I corresponds to the general formula [0361]
wherein substituents R[0362] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₃₂.
Table 33: A further preferred group of compounds of formula I corresponds to the general formula [0363]
wherein substituents R[0364] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₃₃.
Table 34: A further preferred group of compounds of formula I corresponds to the general formula [0365]
wherein substituents R[0366] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₃₄.
Table 35: A further preferred group of compounds of formula I corresponds to the general formula [0367]
wherein substituents R[0368] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₃₅.
Table 36: A further preferred group of compounds of formula I corresponds to the general formula [0369]
wherein substituents R[0370] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₃₆.
Table 37: A further preferred group of compounds of formula I corresponds to the general formula [0371]
wherein substituents R[0372] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₃₇.
Table 38: A further preferred group of compounds of formula I corresponds to the general formula [0373]
wherein substituents R[0374] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₃₈.
Table 39: A further preferred group of compounds of formula I corresponds to the general formula [0375]
wherein substituents R[0376] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₃₉.
Table 40: A further preferred group of compounds of formula I corresponds to the general formula [0377]
wherein substituents R[0378] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₄₀.
Table 41: A further preferred group of compounds of formula I corresponds to the general formula [0379]
wherein substituents R[0380] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₄₁.
Table 42: A further preferred group of compounds of formula I corresponds to the general formula [0381]
wherein substituents R[0382] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₄₂.
Table 43: A further preferred group of compounds of formula I corresponds to the general formula [0383]
wherein substituents R[0384] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₄₃.
Table 44: A further preferred group of compounds of formula I corresponds to the general formula [0385]
wherein substituents R[0386] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₄₄.
Table 45: A further preferred group of compounds of formula I corresponds to the general formula [0387]
wherein substituents R[0388] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₄₅.
Table 46: A further preferred group of compounds of formula I corresponds to the general formula [0389]
wherein substituents R[0390] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₄₆.
Table 47: A further preferred group of compounds of formula I corresponds to the general formula [0391]
wherein substituents R[0392] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₄₇.
Table 48: A further preferred group of compounds of formula I corresponds to the general formula [0393]
wherein substituents R[0394] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₄₈.
Table 49: A further preferred group of compounds of formula I corresponds to the general formula [0395]
wherein substituents R[0396] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₄₉.
Table 50: A further preferred group of compounds of formula I corresponds to the general formula [0397]
wherein substituents R[0398] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₅₀.
Table 51: A further preferred group of compounds of formula I corresponds to the general formula [0399]
wherein substituents R[0400] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₅₁.
Table 52: A further preferred group of compounds of formula I corresponds to the general formula [0401]
wherein substituents R[0402] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₅₂.
Table 53: A further preferred group of compounds of formula I corresponds to the general formula [0403]
wherein substituents R[0404] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₅₃.
Table 54: A further preferred group of compounds of formula I corresponds to the general formula [0405]
wherein substituents R[0406] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₅₄.
Table 55: A further preferred group of compounds of formula I corresponds to the general formula [0407]
wherein substituents R[0408] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₅₅.
Table 56: A further preferred group of compounds of formula I corresponds to the general formula [0409]
wherein substituents R[0410] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₅₆.
Table 57: A further preferred group of compounds of formula I corresponds to the general formula [0411]
wherein substituents R[0412] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₅₇.
Table 58: A further preferred group of compounds of formula I corresponds to the general formula [0413]
wherein substituents R[0414] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₅₈.
Table 59: A further preferred group of compounds of formula I corresponds to the general formula [0415]
wherein substituents R[0416] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₅₉.
Table 60: A further preferred group of compounds of formula I corresponds to the general formula [0417]
wherein substituents R[0418] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₆₀.
Table 61: A further preferred group of compounds of formula I corresponds to the general formula [0419]
wherein substituents R[0420] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₆₁.
Table 62: A further preferred group of compounds of formula I corresponds to the general formula [0421]
wherein substituents R[0422] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₆₂.
Table 63: A further preferred group of compounds of formula I corresponds to the general formula [0423]
wherein substituents R[0424] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₆₃.
Table 64: A further preferred group of compounds of formula I corresponds to the general formula [0425]
wherein substituents R[0426] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₆₄.
Table 65: A further preferred group of compounds of formula I corresponds to the general formula [0427]
wherein substituents R[0428] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₆₅.
Table 66: A further preferred group of compounds of formula I corresponds to the general formula [0429]
wherein substituents R[0430] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₆₆.
Table 67: A further preferred group of compounds of formula I corresponds to the general formula [0431]
wherein substituents R[0432] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₆₇.
Table 68: A further preferred group of compounds of formula I corresponds to the general formula [0433]
wherein substituents R[0434] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₆₈.
Table 69: A further preferred group of compounds of formula I corresponds to the general formula [0435]
wherein substituents R[0436] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₆₉.
Table 70: A further preferred group of compounds of formula I corresponds to the general formula [0437]
wherein substituents R[0438] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₇₀.
Table 71: A further preferred group of compounds of formula I corresponds to the general formula [0439]
wherein substituents R[0440] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₇₁.
Table 72: A further preferred group of compounds of formula I corresponds to the general formula [0441]
wherein substituents R[0442] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₇₂.
Table 73: A further preferred group of compounds of formula I corresponds to the general formula [0443]
wherein substituents R[0444] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₇₃.
Table 74: A further preferred group of compounds of formula I corresponds to the general formula [0445]
wherein substituents R[0446] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₇₄.
Table 75: A further preferred group of compounds of formula I corresponds to the general formula [0447]
wherein substituents R[0448] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₇₅.
Table 76: A further preferred group of compounds of formula I corresponds to the general formula [0449]
wherein substituents R[0450] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₇₆.
Table 77: A further preferred group of compounds of formula I corresponds to the general formula [0451]
wherein substituents R[0452] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₇₇.
Table 78: A further preferred group of compounds of formula I corresponds to the general formula [0453]
wherein substituents R[0454] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₇₈.
Table 79: A further preferred group of compounds of formula I corresponds to the general formula [0455]
wherein substituents R[0456] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₇₉.
Table 80: A further preferred group of compounds of formula I corresponds to the general formula [0457]
wherein substituents R[0458] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₈₀.
Table 81: A further preferred group of compounds of formula I corresponds to the general formula [0459]
wherein substituents R[0460] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₈₁.
Table 82: A further preferred group of compounds of formula I corresponds to the general formula [0461]
wherein substituents R[0462] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₈₂.
Table 83: A further preferred group of compounds of formula I corresponds to the general formula [0463]
wherein substituents R[0464] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₈₃.
Table 84: A further preferred group of compounds of formula I corresponds to the general formula [0465]
wherein substituents R[0466] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₈₄.
Table 85: A further preferred group of compounds of formula I corresponds to the general formula [0467]
wherein substituents R[0468] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₈₅.
Table 86: A further preferred group of compounds of formula I corresponds to the general formula [0469]
wherein substituents R[0470] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₈₆.
Table 87: A further preferred group of compounds of formula I corresponds to the general formula [0471]
wherein substituents R[0472] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₈₇.
Table 88: A further preferred group of compounds of formula I corresponds to the general formula [0473]
wherein substituents R[0474] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₈₈.
Table 89: A further preferred group of compounds of formula I corresponds to the general formula [0475]
wherein substituents R[0476] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₈₉.
Table 90: A further preferred group of compounds of formula I corresponds to the general formula [0477]
wherein substituents R[0478] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₉₀.
Table 91: A further preferred group of compounds of formula I corresponds to the general formula [0479]
wherein substituents R[0480] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₉₁.
Table 92: A further preferred group of compounds of formula I corresponds to the general formula [0481]
wherein substituents R[0482] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₉₂.
Table 93: A further preferred group of compounds of formula I corresponds to the general formula [0483]
wherein substituents R[0484] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₉₃.
Table 94: A further preferred group of compounds of formula I corresponds to the general formula [0485]
wherein substituents R[0486] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₉₄.
Table 95: A further preferred group of compounds of formula I corresponds to the general formula [0487]
wherein substituents R[0488] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₉₅.
Table 96: A further preferred group of compounds of formula I corresponds to the general formula [0489]
wherein substituents R[0490] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₉₆.
Table 97: A further preferred group of compounds of formula I corresponds to the general formula [0491]
wherein substituents R[0492] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₉₇.
Table 98: A further preferred group of compounds of formula I corresponds to the general formula [0493]
wherein substituents R[0494] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₉₈.
Table 99: A further preferred group of compounds of formula I corresponds to the general formula [0495]
wherein substituents R[0496] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₉₉.
Table 100: A further preferred group of compounds of formula I corresponds to the general formula [0497]
wherein substituents R[0498] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₀₀.
Table 101: A further preferred group of compounds of formula I corresponds to the general formula [0499]
wherein substituents R[0500] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₀₁.
Table 102: A further preferred group of compounds of formula I corresponds to the general formula [0501]
wherein substituents R[0502] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₀₂.
Table 103: A further preferred group of compounds of formula I corresponds to the general formula [0503]
wherein substituents R[0504] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₀₃.
Table 104: A further preferred group of compounds of formula I corresponds to the general formula [0505]
wherein substituents R[0506] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₀₄.
Table 105: A further preferred group of compounds of formula I corresponds to the general formula [0507]
wherein substituents R[0508] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₀₅.
Table 106: A further preferred group of compounds of formula I corresponds to the general formula [0509]
wherein substituents R[0510] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₀₆.
Table 107: A further preferred group of compounds of formula I corresponds to the general formula [0511]
wherein substituents R[0512] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₀₇.
Table 108: A further preferred group of compounds of formula I corresponds to the general formula [0513]
wherein substituents R[0514] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₀₈.
Table 109: A further preferred group of compounds of formula I corresponds to the general formula [0515]
wherein substituents R[0516] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₀₉.
Table 110: A further preferred group of compounds of formula I corresponds to the general formula [0517]
wherein substituents R[0518] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₁₀.
Table 111: A further preferred group of compounds of formula I corresponds to the general formula [0519]
wherein substituents R[0520] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₁₁.
Table 112: A further preferred group of compounds of formula I corresponds to the general formula [0521]
wherein substituents R[0522] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₁₂.
Table 113: A further preferred group of compounds of formula I corresponds to the general formula [0523]
wherein substituents R[0524] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₁₃.
Table 114: A further preferred group of compounds of formula I corresponds to the general formula [0525]
wherein substituents R[0526] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₁₄.
Table 115: A further preferred group of compounds of formula I corresponds to the general formula [0527]
wherein substituents R[0528] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₁₅.
Table 116: A further preferred group of compounds of formula I corresponds to the general formula [0529]
wherein substituents R[0530] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₁₆.
Table 117: A further preferred group of compounds of formula I corresponds to the general formula [0531]
wherein substituents R[0532] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₁₇.
Table 118: A further preferred group of compounds of formula I corresponds to the general formula [0533]
wherein substituents R[0534] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₁₈.
Table 1 19: A further preferred group of compounds of formula I corresponds to the general formula [0535]
wherein substituents R[0536] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₁₉.
Table 120: A further preferred group of compounds of formula I corresponds to the general formula [0537]
wherein substituents R[0538] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₂₀.
Table 121: A further preferred group of compounds of formula I corresponds to the general formula [0539]
wherein substituents R[0540] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₂₁.
Table 122: A further preferred group of compounds of formula I corresponds to the general formula [0541]
wherein substituents R[0542] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₂₂.
Table 123: A further preferred group of compounds of formula I corresponds to the general formula [0543]
wherein substituents R[0544] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₂₃.
Table 124: A further preferred group of compounds of formula I corresponds to the general formula [0545]
wherein substituents R[0546] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₂₄.
Table 125: A further preferred group of compounds of formula I corresponds to the general formula [0547]
wherein substituents R[0548] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₂₅.
Table 126: A further preferred group of compounds of formula I corresponds to the general formula [0549]
wherein substituents R[0550] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₂₆.
Table 127: A further preferred group of compounds of formula I corresponds to the general formula [0551]
wherein substituents R[0552] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₂₇.
Table 128: A further preferred group of compounds of formula I corresponds to the general formula [0553]
wherein substituents R[0554] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₂₈.
Table 129: A further preferred group of compounds of formula I corresponds to the general formula [0555]
wherein substituents R[0556] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₂₉.
Table 130: A further preferred group of compounds of formula I corresponds to the general formula [0557]
wherein substituents R[0558] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₃₀.
Table 131: A further preferred group of compounds of formula I corresponds to the general formula [0559]
wherein substituents R[0560] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₃₁.
Table 132: A further preferred group of compounds of formula I corresponds to the general formula [0561]
wherein substituents R[0562] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₃₂.
Table 133: A further preferred group of compounds of formula I corresponds to the general formula [0563]
wherein substituents R[0564] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₃₃.
Table 134: A further preferred group of compounds of formula I corresponds to the general formula [0565]
wherein substituents R[0566] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₃₄.
Table 135: A further preferred group of compounds of formula I corresponds to the general formula [0567]
wherein substituents R[0568] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₃₅.
Table 136: A further preferred group of compounds of formula I corresponds to the general formula [0569]
wherein substituents R[0570] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₃₆.
Table 137: A further preferred group of compounds of formula I corresponds to the general formula [0571]
wherein substituents R[0572] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₃₇.
Table 138: A further preferred group of compounds of formula I corresponds to the general formula [0573]
wherein substituents R[0574] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₃₈.
Table 139: A further preferred group of compounds of formula I corresponds to the general formula [0575]
wherein substituents R[0576] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₃₉.
Table 140: A further preferred group of compounds of formula I corresponds to the general formula [0577]
wherein substituents R[0578] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₄₀.
Table 141: A further preferred group of compounds of formula I corresponds to the general formula [0579]
wherein substituents R[0580] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₄₁.
Table 142: A further preferred group of compounds of formula I corresponds to the general formula [0581]
wherein substituents R[0582] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₄₂.
Table 143: A further preferred group of compounds of formula I corresponds to the general formula [0583]
wherein substituents R[0584] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₄₃.
Table 144: A further preferred group of compounds of formula I corresponds to the general formula [0585]
wherein substituents R[0586] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₄₄.
Table 145: A further preferred group of compounds of formula I corresponds to the general formula [0587]
wherein substituents R[0588] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₄₅.
Table 146: A further preferred group of compounds of formula I corresponds to the general formula [0589]
wherein substituents R[0590] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₄₆.
Table 147: A further preferred group of compounds of formula I corresponds to the general formula [0591]
wherein substituents R[0592] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₄₇.
Table 148: A further preferred group of compounds of formula I corresponds to the general formula [0593]
wherein substituents R[0594] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₄₈.
Table 149: A further preferred group of compounds of formula I corresponds to the general formula [0595]
wherein substituents R[0596] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₄₉.
Table 150: A further preferred group of compounds of formula I corresponds to the general formula [0597]
wherein substituents R[0598] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₅₀.
Table 151: A further preferred group of compounds of formula I corresponds to the general formula [0599]
wherein substituents R[0600] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₅₁.
Table 152: A further preferred group of compounds of formula I corresponds to the general formula [0601]
wherein substituents R[0602] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₅₂.
Table 153: A further preferred group of compounds of formula I corresponds to the general formula [0603]
wherein substituents R[0604] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₅₃.
Table 154: A further preferred group of compounds of formula I corresponds to the general formula [0605]
wherein substituents R[0606] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₅₄.
Table 155: A further preferred group of compounds of formula I corresponds to the general [0607]
wherein substituents R[0608] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₅₅.
Table 156: A further preferred group of compounds of formula I corresponds to the general formula [0609]
wherein substituents R[0610] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₅₆.
Table 157: A further preferred group of compounds of formula I corresponds to the general formula [0611]
wherein substituents R[0612] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₅₇.
Table 158: A further preferred group of compounds of formula I corresponds to the general formula [0613]
wherein substituents R[0614] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₅₈.
Table 159: A further preferred group of compounds of formula I corresponds to the general formula [0615]
wherein substituents R[0616] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₅₉.
Table 160: A further preferred group of compounds of formula I corresponds to the general formula [0617]
wherein substituents R[0618] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₆₀.
Table 161: A further preferred group of compounds of formula I corresponds to the general formula [0619]
wherein substituents R[0620] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₆₁.
Table 162: A further preferred group of compounds of formula I corresponds to the general formula [0621]
wherein substituents R[0622] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₆₂.
Table 163: A further preferred group of compounds of formula I corresponds to the general formula [0623]
wherein substituents R[0624] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₆₃.
Table 164: A further preferred group of compounds of formula I corresponds to the general formula [0625]
wherein substituents R[0626] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₆₄.
Table 165: A further preferred group of compounds of formula I corresponds to the general formula [0627]
wherein substituents R[0628] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₆₅.
Table 166: A further preferred group of compounds of formula I corresponds to the general formula [0629]
wherein substituents R[0630] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₆₆.
Table 167: A further preferred group of compounds of formula I corresponds to the general formula [0631]
wherein substituents R[0632] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₆₇.
Table 168: A further preferred group of compounds of formula I corresponds to the general formula [0633]
wherein substituents R[0634] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₆₈.
Table 169: A further preferred group of compounds of formula I corresponds to the general formula [0635]
wherein substituents R[0636] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₆₉.
Table 170: A further preferred group of compounds of formula I corresponds to the general formula [0637]
wherein substituents R[0638] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₇₀.
Table 171: A further preferred group of compounds of formula I corresponds to the general formula [0639]
wherein substituents R[0640] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₇₁.
Table 172: A further preferred group of compounds of formula I corresponds to the general formula [0641]
wherein substituents R[0642] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₇₂.
Table 173: A further preferred group of compounds of formula I corresponds to the general formula [0643]
wherein substituents R[0644] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₇₃.
Table 174: A further preferred group of compounds of formula I corresponds to the general formula [0645]
wherein substituents R[0646] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₇₄.
Table 175: A further preferred group of compounds of formula I corresponds to the general formula [0647]
wherein substituents R[0648] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₇₅.
Table 176: A further preferred group of compounds of formula I corresponds to the general formula [0649]
wherein substituents R[0650] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₇₆.
Table 177: A further preferred group of compounds of formula I corresponds to the general formula [0651]
wherein substituents R[0652] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₇₇.
Table 178: A further preferred group of compounds of formula I corresponds to the general formula [0653]
wherein substituents R[0654] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₇₈.
Table 179: A further preferred group of compounds of formula I corresponds to the general formula [0655]
wherein substituents R[0656] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₇₉.
Table 180: A further preferred group of compounds of formula I corresponds to the general formula [0657]
wherein subsituents R[0658] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₈₀.
Table 181: A further preferred group of compounds of formula I corresponds to the general formula [0659]
wherein substituents R[0660] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₈₁.
Table 182: A further preferred group of compounds of formula I corresponds to the general formula [0661]
wherein substituents R[0662] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₈₂.
Table 183: A further preferred group of compounds of formula I corresponds to the general formula [0663]
wherein substituents R[0664] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₈₃.
Table 184: A further preferred group of compounds of formula I corresponds to the general formula [0665]
wherein substituents R[0666] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₈₄.
Table 185: A further preferred group of compounds of formula I corresponds to the general formula [0667]
wherein substituents R[0668] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₈₅.
Table 186: A further preferred group of compounds of formula I corresponds to the general formula [0669]
wherein substituents R[0670] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₈₆.
Table 187: A further preferred group of compounds of formula I corresponds to the general formula [0671]
wherein substituents R[0672] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₈₇.
Table 188: A further preferred group of compounds of formula I corresponds to the general formula [0673]
wherein substituents R[0674] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₈₈.
Table 189: A further preferred group of compounds of formula I corresponds to the general formula [0675]
wherein substituents R[0676] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₈₉.
Table 190: A further preferred group of compounds of formula I corresponds to the general formula [0677]
wherein substituents R[0678] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₉₀.
Table 191: A further preferred group of compounds of formula I corresponds to the general formula [0679]
wherein substituents R[0680] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₉₁.
Table 192: A further preferred group of compounds of formula I corresponds to the general formula [0681]
wherein substituents R[0682] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₉₂.
Table 193: A further preferred group of compounds of formula I corresponds to the general formula [0683]
wherein substituents R[0684] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₉₃.
Table 194: A further preferred group of compounds of formula I corresponds to the general formula [0685]
wherein substituents R[0686] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₉₄.
Table 195: A further preferred group of compounds of formula I corresponds to the general formula [0687]
wherein substituents R[0688] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₉₅.
Table 196: A further preferred group of compounds of formula I corresponds to the general formula [0689]
wherein substituents R[0690] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₉₆.
Table 197: A further preferred group of compounds of formula I corresponds to the general formula [0691]
wherein substituents R[0692] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₉₇.
Table 198: A further preferred group of compounds of formula I corresponds to the general formula [0693]
wherein substituents R[0694] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₉₈.
Table 199: A further preferred group of compounds of formula I corresponds to the general formula [0695]
wherein substituents R[0696] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₉₉.
Table 200: A further preferred group of compounds of formula I corresponds to the general formula [0697]
wherein substituents R[0698] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₂₀₀.
Table 201: A further preferred group of compounds of formula I corresponds to the general formula [0699]
wherein substituents R[0700] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₂₀₁.
Table 202: A further preferred group of compounds of formula I corresponds to the general formula [0701]
wherein substituents R[0702] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₂₀₂.
Table 203: A further preferred group of compounds of formula I corresponds to the general formula [0703]
wherein substituents R[0704] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₂₀₃.
Table 204: A further preferred group of compounds of formula I corresponds to the general formula [0705]
wherein substituents R[0706] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₂₀₄.
Table 205: A further preferred group of compounds of formula I corresponds to the general formula [0707]
wherein substituents R[0708] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₂₀₅.
Table 206: A further preferred group of compounds of formula I corresponds to the general formula [0709]
wherein substituents R[0710] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₂₀₆.
Table 207: A further preferred group of compounds of formula I corresponds to the general formula [0711]
wherein substituents R[0712] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₂₀₇.
Table 208: A further preferred group of compounds of formula I corresponds to the general formula [0713]
wherein substituents R[0714] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₂₀₈
Table 209: A further preferred group of compounds of formula I corresponds to the general formula [0715]
wherein substituents R[0716] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₂₀₉
Table 210: A further preferred group of compounds of formula I corresponds to the general formula [0717]
wherein substituents R[0718] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₂₁₀.
Table 211: A further preferred group of compounds of formula I corresponds to the general formula [0719]
wherein substituents R[0720] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₂₁₁.
Table 212: A further preferred group of compounds of formula I corresponds to the general formula [0721]
wherein substituents R[0722] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₂₁₂.
Table 213: A further preferred group of compounds of formula I corresponds to the general formula [0723]
wherein substituents R[0724] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₂₁₃.
Table 214: A further preferred group of compounds of formula I corresponds to the general formula [0725]
wherein substituents R[0726] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₂₁₄.
Table 215: A further preferred group of compounds of formula I corresponds to the general formula [0727]
wherein substituents R[0728] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₂₁₅.
Table 216: A further preferred group of compounds of formula I corresponds to the general formula [0729]
wherein substituents R[0730] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₂₁₆.
Table 217: A further preferred group of compounds of formula I corresponds to the general formula [0731]
wherein substituents R[0732] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₂₁₇.
Table 218: A further preferred group of compounds of formula I corresponds to the general formula [0733]
wherein substituents R[0734] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₂₁₈.
Table 219: A further preferred group of compounds of formula I corresponds to the general formula [0735]
wherein substituents R[0736] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₂₁₉.
Table 220: A further preferred group of compounds of formula I corresponds to the general formula [0737]
wherein substituents R[0738] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₂₂₀.
Table 221: A further preferred group of compounds of formula I corresponds to the general formula [0739]
wherein substituents R[0740] ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₂₂₁.
Table 222: A further preferred group of compounds of formula I corresponds to the general formula [0741]

wherein substituents R ₁and R₃are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₂₂₂.

TABLE A


Cmpd no.	R₁	R₃

.001	F	CN
.002	F	CHO
.003	F	COCH₃
.004	F	COOCH₂CH₃
.005	F	COOCH₂C₆H₅
.006	F	COCl
.007	F	COCH₂CH₂Cl
.008	F	COOH
.009	F	COOCH₃
.010	F	COOCH₂CH₃
.011	F	COOCH(CH₃)₂
.012	F	COOCH₂CH═CH₂
.013	F	COO(CH₂)₅CH₃
.014	F	COOCH(CH₃)CH═CH₂
.015	F	COOCH₂(2-F-C₆H₅)
.016	F	COOC₆H₅
.017	F	COOCH₂CH₂OCH₂CH₃
.018	F	COOCH(CH₃)CH₂SCH₃
.019	F	COO(oxetanyl)
.020	F	COOCH₂(oxiranyl)
.021	F	COO(cylopentyl)
.022	F	COSCH₃
.023	F	COSCH(CH₃)₂
.024	F	COSCH₂C₆H₅
.025	F	CONH₂
.026	F	CONH(CH₂CH═CH₂)
.027	F	CONHCH₂C₆H₅
.028	F	CON(CH₂CH═CH₂)₂
.029	F	CON(CH₃)OCH₃
.030	F	COOCH₂CH₂COOH
.031	F	COOCH(CH₃)COOCH₃
.032	F	COOCH(CH₃)COOCH₂C₆H₅
.033	F	COOCH(CH₃)CH₂COOCH₂CH₃
.034	F	(S)-COOCH(CH₃)CH₂COOCH₂CH═CH₂
.035	F	(R)-COOCH(CH₃)CH₂COOCH₂CH═CH₂
.036	F	COOCH(CH₃)CH₂CONHCH₂CH₃
.037	F	COOCH(CH₃)CH₂CON(CH₃)2
.038	F	(R)-COOCH(CH₃)CH₂COOCH₃
.039	F	COOCH(CH₃)CH₂COOCH₂CH═CH₂
.040	F	COOC(CH₃)₂COCH₃
.041	F	COOC(CH₃)₂COOH
.042	F	COOC(CH₃)₂COOCH₃
.043	F	COOC(CH₃)₂COOCH₂CH₃
.044	F	COOC(CH₃)₂COOCH(CH₃)₂
.045	F	COOC(CH₃)₂COO(CH₂)₄CH₃
.046	F	COOC(CH₃)COOCH₂C₆H₅
.047	F	COOC(CH₃)₂COOCH₂(2-F-C₆H₅₎
.048	F	COOC(CH₃)₂COOCH₂CH═CH₂
.049	F	(R)-COOCH(CH₃)COOCH₂CH₃
.050	F	COOC(CH₃)₂COOCH₂C≡CH
.051	F	COO(CH₃)₂COOCH₂CH₂OCH₂CH₃
.052	F	COOC(CH₃)₂COSCH₃
.053	F	COOC(CH₃)₂COSCH(CH₃)₂
.054	F	COOC(CH₃)₂COSCH₂C₆H₅
.055	F	COOC(CH₃)₂CONH₂
.056	F	COOC(CH₃)₂CONHCH₂CH═CH₂
.057	F	COOC(CH₃)₂CON(CH₂CH₃)₂
.058	F	COOC(CH₃)₂CON(CH₃)CH₂CH₂OCH₃
.059	F	COSCH(CH₃)COOH
.060	F	COSCH(CH₃)COOCH₃
.061	F	COSCH(CH₃)CONHCH₂CH═CH₂
.062	F	CON(CH₃)CH₂COOH
.063	F	CON(CH₃)C(CH₃)₂COOCH₂CH₃
.064	F	CON(CH₃)OCH₂COOCH₃
.065	F	CON(CH₃)OH
.066	F	CH₃
.067	F	CH₂CH₃
.068	F	CH(OH)CH₃
.069	F	CH(OCH₂CH═CH₂)CH₃
.070	F	CH₂Cl
.071	F	CH₂OH
.072	F	CH₂OCOCH₃
.073	F	CHClCH₃
.074	F	CH₂CH₂CF₃
.075	F	CH═CHCF₃
.076	F	CH₂CH═CH₂
.077	F	CH═CHCH₃
.078	F	C≡CH
.079	F	CCCH₂OH
.080	F	CH₂CHClCOOH
.081	F	(R)-CH₂CHClCOOH
.082	F	(S)-CH₂CHClCOOH
.083	F	CH₂CH(CH₃)COOH
.084	F	CH₂CH(CH₃)COOCH₂CH₃
.085	F	CH(Cl)CH₂COOCH₃
.086	F	CH(Cl)C(Cl)₂COOH
.087	F	CH(Cl)CH(Cl)COOCH₂CH₃
.088	F	CH₂CH(CH₃COOH
.089	F	CH₂CH(CH₃)COCH₂CH═CH₂
.090	F	CH₂CH(CH₃)CONH(CH₂CH═CH₂)
.091	F	CH₂CH(CH₃)CON(CH₃)₂
.092	F	CH₂CH(CH₃)COSCH(CH₃)₂
.093	F	CH₂CHClCOOC(CH₃)₃
.094	F	CH₂CHClCOOCH₃
.095	F	CH₂CHClCOOCH₂CH₃
.096	F	CH₂CHClCOOCH(CH₃)₂
.097	F	CH₂CHClCOOCH₂CH═CH₂
.098	F	CH₂CHClCOOCH₂C₆H₅
.099	F	CH₂CHClCOSCH₃
.100	F	CH₂CHClCOSCH(CH₃)₂
.101	F	CH₂CHClCOSCH₂C₆H₅
.102	F	CH₂CHClCONH₂
.103	F	CH₂CHClCONH(CH₂CHCH₂)
.104	F	CH₂CHClCON(CH₂CH₃)₂
.105	F	CH₂CHClCONH(CH₂C₆H₅₎
.106	F	CH₂CHClCON(CH₃)CH₂C₆H₅
.107	F	CH═CHCOOH
.108	F	(E)-CH═CHCOOH
.109	F	(Z)-CH═CHCOOH
.110	F	CH═CHCOOCH₃
.111	F	CH═CHCOOCH₂C₆H₅
.112	F	CH═CHCONH₂
.113	F	CH═CHCONH(CH₂CH═CH₂)
.114	F	CH═C(Cl)COOH
.115	F	CH═C(Cl)CONH₂
.116	F	CH═C(Cl)CONH(CH₂CH₃)
.117	F	CH═C(Cl)CON(CH₂CH₃)₂
.118	F	CH═C(Cl)CONH(CH₂C₆H₅)
.119	F	CH═C(Cl)COSCH₃
.120	F	CH═C(Cl)COSCH(CH₃)₂
.121	F	CH═C(CH₃)COOH
.122	F	CH═C(CH₃)CONH(CH₂CH═CH₂)
.123	F	CH═C(CH₃)CON(CH₃)₂
.124	F	CH═C(CH₃)COSCH₂CH₃
.125	F	CH═C(CN)COOH
.126	F	CH═C(CN)COOC(CH₃)₃
.127	F	CH═C(CN)CON(CH₂CH═CH₂)₂
.128	F	CH═C(COOH)₂
.129	F	CH═C(C₆H₅)COOH
.130	F	CH═CHCH₂OH
.131	Cl	CN
.132	Cl	CHO
.133	Cl	COCH₃
.134	Cl	COOCH₂CH₃
.135	Cl	COOCH₂C₆H₅
.136	Cl	COCl
.137	Cl	COCH₂CH₂Cl
.138	Cl	COOH
.139	Cl	COOCH₃
.140	Cl	COOCH₂CH₃
.141	Cl	COOCH(CH₃)₂
.142	Cl	COOCH₂CH═CH₂
.143	Cl	COO(CH₂)₅CH₃
.144	Cl	COOCH(CH₃)CH═CH₂
.145	Cl	COOCH₂(2-F-C₆H₅)
.146	Cl	COOC₆H₅
.147	Cl	COOCH₂CH₂OCH₂CH₃
.148	Cl	COOCH(CH₃)CH₂SCH₃
.149	Cl	COO(oxetanyl)
.150	Cl	COOCH₂(oxiranyl)
.151	Cl	COO(cylopentyl)
.152	Cl	COSCH₃
.153	Cl	COSCH(CH₃)₂
.154	Cl	COSCH₂C₆H₅
.155	Cl	CONH₂
.156	Cl	CONH(CH₂CH═CH₂)
.157	Cl	CONHCH₂C₆H₅
.158	Cl	CON(CH₂CH═CH₂)₂
.159	Cl	CON(CH₃)OCH₃
.160	Cl	COOCH₂CH₂COOH
.161	Cl	COOCH(CH₃)COOCH₃
.162	Cl	COOCH(CH₃)COOCH₂C₆H₅
.163	Cl	COOCH(CH₃)CH₂COOCH₂CH₃
.164	Cl	(S)-COOCH(CH₃)CH₂COOCH₂CHCH₂
.165	Cl	(R)-COOCH(CH₃)CH₂COOCH₂CHCH₂
.166	Cl	COOCH(CH₃)CH₂CONHCH₂CH₃
.167	Cl	COOCH(CH₃)CH₂CON(CH₃)₂
.168	Cl	COOCH(CH₃)CH₂COSCH₂CH₃
.169	Cl	COOCH(CH₃)CH₂COOCH₂CH═CH₂
.170	Cl	COOC(CH₃)₂COCH₃
.171	Cl	COOC(CH₃)₂COOH
.172	Cl	COOC(CH₃)₂COOCH₃
.173	Cl	COOC(CH₃)₂COOCH₂CH₃
.174	Cl	COOC(CH₃)₂COOCH(CH₃)₂
.175	Cl	COOC(CH₃)₂COO(CH₂)₄CH₃
.176	Cl	COOC(CH₃)₂COOCH₂C₆H₅
.177	Cl	COOC(CH₃)₂COOCH₂(2-F-C₆H₅₎
.178	Cl	COOC(CH₃)₂COOCH₂CH═CH₂
.179	Cl	COOC(CH₃)₂COOCH(CH₃)CH═CH₂
.180	Cl	COOC(CH₃)₂COOCH₂C≡CH
.181	Cl	COO(CH₃)₂COOCH₂CH₂OCH₂CH₃
.182	Cl	COOC(CH₃)₂COSCH₃
.183	Cl	COOC(CH₃)₂COSCH(CH₃)₂
.184	Cl	COOC(CH₃)₂COSCH₂C₆H₅
.185	Cl	COOC(CH₃)₂CONH₂
.186	Cl	COOC(CH₃)₂CONHCH₂CH═CH₂
.187	Cl	COOC(CH₃)₂CON(CH₂CH₃)₂
.188	Cl	COOC(CH₃)₂CON(CH₃)CH₂CH₂OCH₃
.189	Cl	COSCH(CH₃)COOH
.190	Cl	COSCH(CH₃)COOCH₃
.191	Cl	COSCH(CH₃)CONHCH₂CH═CH₂
.192	Cl	CON(CH₃)CH₂COOH
.193	Cl	CON(CH₃)C(CH₃)₂COOCH₂CH₃
.194	Cl	CON(CH₃)OCH₂COOCH₃
.195	Cl	CON(CH₃)OH
.196	Cl	CH₃
.197	Cl	CH₂CH₃
.198	Cl	CH(OH)CH₃
.199	Cl	CH(OCH₂CH═CH₂)CH₃
.200	Cl	CH₂Cl
.201	Cl	CH₂OH
.202	Cl	CH₂OCOCH₃
.203	Cl	CHClCH₃
.204	Cl	CH₂CH₂CF₃
.205	Cl	CH═CHCF₃
.206	Cl	CH₂CH═CH₂
.207	Cl	CH═CH(CH₃)
.208	Cl	C≡CH
.209	Cl	C≡CCH₂OH
.210	Cl	CH₂CHClCOOH
.211	Cl	(R)-CH₂CHClCOOH
.212	Cl	(S)-CH₂CHClCOOH
.213	Cl	CH₂CH(CH₃)COOH
.214	Cl	CH₂CH(CH₃)COOCH₂CH₃
.215	Cl	CH(Cl)CH₂COOCH₃
.216	Cl	CH(Cl)C(Cl)₂COOH
.217	Cl	CH(Cl)CH(Cl)COOCH₂CH₃
.218	Cl	CH₂CH(CH₃)COOH
.219	Cl	CH₂CH(CH₃)COCH₂CH═CH₂
.220	Cl	CH₂CH(CH₃)CONH(CH₂CH═CH₂)
.221	Cl	CH₂CH(CH₃)CON(CH₃)₂
.222	Cl	CH₂CH(CH₃)COSCH(CH₃)₂
.223	Cl	CH₂CHClCOOC(CH₃)₃
.224	Cl	CH₂CHClCOOCH₃
.225	Cl	CH₂CHClCOOCH₂CH₃
.226	Cl	CH₂CHClCOOCH(CH₃)₂
.227	Cl	CH₂CHClCOOCH₂CH═CH₂
.228	Cl	CH₂CHClCOOCH₂C₆H₅
.229	Cl	CH₂CHClCOSCH₃
.230	Cl	CH₂CHClCOSCH(CH₃)₂
.231	Cl	CH₂CHClCOSCH₂C₆H₅
.232	Cl	CH₂CHClCONH₂
.233	Cl	CH₂CHClCONH(CH₂CH═CH₂)
.234	Cl	CH₂CHClCON(CH₂CH₃)₂
.235	Cl	CH₂CHClCONH(CH₂C₆H₅₎
.236	Cl	CH₂CHClCON(CH₃)CH₂C₆H₅
.237	Cl	CH═CHCOOH
.238	Cl	(E)-CH═CHCOOH
.239	Cl	(Z)-CH═CHCOOH
.240	Cl	CH═CHCOOCH₃
.241	Cl	CH═CHCOOCH₂C₆H₅
.242	Cl	CH═CHCOONH₂
.243	Cl	CH═CHCONH(CH₂CHCH₂)
.244	Cl	CH═C(Cl)COOH
.245	CI	CH═C(Cl)CONH₂
.246	Cl	CH═C(Cl)CONH(CH₂CH₃)
.247	Cl	CH═C(Cl)CON(CH₂CH₃)₂
.248	Cl	CH═C(Cl)CONH(CH₂C₆H₅)
.249	Cl	CH═C(Cl)COSCH₃
.250	Cl	CH═C(Cl)COSCH(CH₃)₂
.251	Cl	CH═C(CH₃)COOH
.252	Cl	CH═C(CH₃)CONH(CH₂CHCH₂)
.253	Cl	CH═C(CH₃)CON(CH₃)₂
.254	Cl	CH═C(CH₃)COSCH₂CH₃
.255	Cl	CH═C(CN)COOH
.256	Cl	CH═C(CN)COOC(CH₃)₃
.257	Cl	CH═C(CN)CON(CH₂CHCH₂)₂
.258	Cl	CH═C(COOH)₂
.259	Cl	CH═C(C₆H₅)COOH
.260	Cl	CH═CHCH₂OH
.261	H	CH₂OCOCH₃
.262	H	COOH
.263	H	COCl
.264	H	COOCH₃
.265	H	COOCH(CH₃)₂
.266	H	COOCH₂C₆H₅
.267	H	COSCH(CH₃)₂
.268	H	CONH₂
.269	H	CONHCH₂C₆H₅
.270	H	CON(CH₂CH═CH₂)₂
.271	H	CON(CH₃)OCH₃
.272	H	COOCH(CH₃)CH₂COOH
.273	H	COOCH(CH₃)COOCH₂CH₃
.274	H	COOCH(CH₃)CH₂COOCH₂CH═CH₂
.275	H	COOCH(CH₃)CH₂COSCH₂CH₃
.276	H	COOCH(CH₃)CH₂CONH₂
.277	H	COOCH(CH₃)CH₂CONH(CH₂CHCH₂)
.278	H	COOCH(CH₃)COOH
.279	H	COOC(CH₃)₂COOH
.280	H	COOC(CH₃)₂COOCH₃
.281	H	COOC(CH₃)₂COOCH(CH₃)₂
.282	H	COOC(CH₃)₂COOCH₂CH₃
.283	H	COOC(CH₃)₂COOCH₂CH═CH₂
.284	H	COOC(CH₃)₂COOCH₂CH₂OCH₂CH₃
.285	H	Cyclopropyl
.286	H	COOC(CH₃)₂CON(CH₃)₂
.287	H	COOC(CH₃)₂CONH(CH₂CHCH₂)
.288	H	COSCH(CH₃)COOH
.289	H	CON(CH₃)C(CH₃)COOH
.290	H	CH₃
.291	H	CH₂CH₃
.292	H	CH(OH)CH₃
.293	H	CH₂Cl
.294	H	CH₂OH
.295	H	CH₂OCOCH₃
.296	H	CH═CHCF₃
.297	H	CH₂CH₂CF₃
.298	H	CH₂CH═CH₂
.299	H	CH₂CHClCOOH
.300	H	CH₂CHClCOOCH₂CH₃
.301	H	CH₂CHClCOOCH₂C₆H₅
.302	H	CH₂CHClCOOCH₂CH═CH₂
.303	H	CH₂CHClCOOC(CH₃)₃
.304	H	CH₂CHClCOSCH(CH₃)₂
.305	H	CH₂CHClCONH₂
.306	H	CH₂CHClCONH(CH₂CH₃)
.307	H	CH₂CHClCON(CH₃)₂
.308	H	CH(Cl)CH(Cl)COOH
.309	H	CH₂C(CH₃)ClCOOH
.310	H	CH₂C(CH₃)ClCOOCH₂CH₃
.311	H	CH₂C(CH₃)ClCOSCH₃
.312	H	CH₂C(CH₃)ClCONH(CH₂CH═CH₂)
.313	H	Cyclopropyl
.314	H	CH═CHCOOH
.315	H	CH═C(CH₃)COOH
.316	H	CH═C(Cl)COOH
.317	H	CH═C(CN)COOH
.318	H	CH═C(CN)COOCH₂CH═CH₂
.319	H	CH═C(Cl)COOCH₂CH₃
.320	H	CCCH₃
.321	H	CH═C(Cl)COSCH₂CH₃
.322	H	CH═C(Cl)CON(CH₃)₂
.323	CH₃	CH₂OCOCH₃
.324	CH₃	COOH
.325	CH₃	COCl
.326	CH₃	COOCH₃
.327	CH₃	COOCH(CH₃)₂
.328	CH₃	COOCH₂C₆H₅
.329	CH₃	COSCH(CH₃)₂
.330	CH₃	CONH₂
.331	CH₃	CONHCH₂C₆H₅
.332	CH₃	CON(CH₂CH═CH₂)₂
.333	CH₃	CON(CH₃)OCH₃
.334	CH₃	COOCH(CH₃)CH₂COOH
.335	F	CCH
.336	CH₃	COOCH(CH₃)CH₂COOCH₂CH═CH₂
.337	CH₃	COOCH(CH₃)CH₂COSCH₂CH₃
.338	CH₃	COOCH(CH₃)CH₂CONH₂
.339	CH₃	COOCH(CH₃)CH₂CONH(CH₂CH═CH₂₎
.340	CH₃	COOCH(CH₃)COOH
.341	CH₃	COOC(CH₃)₂COOH
.342	CH₃	COOC(CH₃)₂COOCH₃
.343	CH₃	COOC(CH₃)₂COOCH(CH₃)₂
.344	CH₃	COOC(CH₃)₂COOCH₂CH₃
.345	CH₃	COOC(CH₃)₂COOCH₂CH═CH₂
.346	CH₃	COOC(CH₃)₂COOCH₂CH₂OCH₂CH₃
.347	CH₃	COOC(CH₃)₂CONH₂
.348	CH₃	COOC(CH₃)₂CON(CH₃)₂
.349	CH₃	COOC(CH₃)₂CONH(CH₂CH═CH₂)
.350	CH₃	COSCH(CH₃)COOH
.351	F	CCC(CH₃)₂OH
.352	F	CF₃
.353	CH₃	CH₂CH₃
.354	CH₃	CH(OH)CH₃
.355	CH₃	CH₂Cl
.356	CH₃	CH₂OH
.357	CH₃	CH₂OCOCH₃
.358	CH₃	CH═CHCF₃
.359	CH₃	CH₂CH₂CF₃
.360	CH₃	CH₂CH═CH₂
.361	CH₃	CH₂CHClCOOH
.362	CH₃	CH₂CHClCOOCH₂CH₃
.363	CH₃	CH₂CHClCOOCH₂C₆H₅
.364	CH₃	CH₂CHClCOOCH₂CH═CH₂
.365	CH₃	CH₂CHClCOOC(CH₃)₃
.366	CH₃	CH₂CHClCOSCH(CH₃)₂
.367	CH₃	CH₂CHClCONH₂
.368	Cl	CCC(CH₃)₂OCH₃
.369	F	CCC(CH₃)₂OCH₃
.370	CH₃	CH(Cl)CH(Cl)COOH
.371	CH₃	CH₂C(CH₃)ClCOOH
.372	CH₃	CH₂C(CH₃)ClCOOCH₂CH₃
.373	CH₃	CH₂C(CH₃)ClCOSCH₃
.374	CH₃	CH₂C(CH₃)ClCONH(CH₂CH═CH₂)
.375	CH₃	CH₂C(CH₃)ClCON(CH₃)(CH₂CH═CH₂)
.376	CH₃	CH═CHCOOH
.377	CH₃	CH═C(CH₃)COOH
.378	CH₃	CH═C(Cl)COOH
.379	CH₃	CH═C(CN)COOCH₂CH═CH2
.380	CH₃	CH═C(CN)COOH
.381	CH₃	CH═C(Cl)COOCH₂CH₃
.382	CH₃	CH═C(CH₃)CONH(CH₂CH═CH₂)
.383	CH₃	CH═C(Cl)COSCH₂CH₃
.384	CH₃	CH═C(Cl)CON(CH₃)₂
.385	H	COOCH₂CH₃
.386	CH₃	COOCH₂CH₃
.387	F	CH═CH₂
.388	F	COSCH₂CH₃
.389	F	COO⁻⁺NH₂(CH(CH₃)₂)₂
.390	F	COO⁻⁺NH(CH₂CH₂OH)₃
.391	F	COO⁻⁺K
.392	F	COOCH₂CH(CH₃)CF₃
.393	F	COOCH(CH₃)COOCH₂CH₃
.394	F	CON(CH₂CH₂CH₃)₂
.395	F	COOCH₂CH₂CH₂CH₂CH₃
.396	F	COOCH₂CH₂SCH₂CH₂CH₂CH₃
.397	F	COOCH₂CH₂CN
.398	F	COOCH₂CH₂SCH(CH₃)₂
.399	F	COOCH₂CH₂CH₂C₆H₅
.400	F	COOCH(CH₃)CH₂CH₂CH₃
.401	F	COO(CH₂)₅COOCH₂CH₃
.402	F	COOC(CH₃)₃
.403	F	CH═C(CH₃)COOCH₂CH₃
.404	F	COO-cyclopropyl
.405	F	COO-cyclohexyl
.406	F	COOCH₂-cyclopropyl
.407	F	COOCH₂C₆H₅
.408	F	COOCH₂CH₂OCH₃
.409	F	COOCH₂CH₂CH₃
.410	F	COOCH₂CH(CH₃)₂
.411	F	COOCH₂CH₂CH₂CH₃
.412	F	COOCH₂CH(CH₃)CH₂CH₃
.413	F	COOCH₂(p-Cl-C₆H₄)
.414	F	COOCH(CH₃)C₆H₅
.415	F	COSCH₂(o-F-C₆H₄)
.416	F	COSCH(CH₃)CH₂CH₃
.417	F	COSCH(CH₃)C₆H₅
.418	F	COSCH₂CH₂CH₃
.419	F	COSCH₂CH═CH₂
.420	F	CON(CH₂CH═CH₂)CH₂CH₃
.421	F	CON(SO₂CH₃)CH₃
.422	F	CON(SO₂CH₃)CH₂CH═CH₂
.423	Cl	COO-cyclopropyl
.424	Cl	COO-cyclohexyl
.425	Cl	COOCH₂-oyclopropyl
.426	Cl	COOCH₂C₆H₅
.427	Cl	COOCH₂CH₂OCH₃
.428	Cl	COOCH₂CH₂CH₃
.429	Cl	COOCH₂CH(CH₃)₂
.430	Cl	COOCH₂CH₂CH₂CH₃
.431	Cl	COOCH₂CH(CH₃)CH₂CH₃
.432	Cl	COOCH₂(p-Cl-C₆H₄)
.433	Cl	COOCH(CH₃)C₆H₅
.434	Cl	COOCH(CH₃)C₆H₅
.435	Cl	COSCH₂(o-F-C₆H₄₎
.436	Cl	COSCH(CH₃)CH₂CH₃
.437	Cl	COSCH(CH₃)C₆H₅
.438	Cl	COSCH₂CH₂CH₃
.439	Cl	COSCH₂CH═CH₂
.440	Cl	CON(CH₂CH═CH₂)CH₂CH₃
.441	Cl	CON(SO₂CH₃)CH₃
.442	Cl	CON(SO₂CH₃)CH₂CH═CH₂
.443	H	COOC(CH₃)COCl
.444	F	CH═C(F)COOCH₂CH₃ (E/Z)
.445	F	CH═C(Cl)COOCH₂CH₃ (E/Z)
.446	F	Cl
.447	F	Br
.448	F	I

The intermediate products of formulae XXXIX and XXXX (e.g. in reaction scheme 12) are new and likewise comprise part of the invention. The following tables 600 to 647 exemplify preferred compounds of formulae XXXIX and XXXX. [0743]
Table 600: A preferred group of compounds of formula XXXIX corresponds to the general formula [0744]
wherein substituents R[0745] ₁and R₂are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXIX
Table 601: A further preferred group of compounds of formula XXXIX corresponds to the general formula [0746]
wherein substituents R[0747] ₁and R₂are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXIX₆₀₁.
Table 602: A further preferred group of compounds of formula XXXIX corresponds to the general formula [0748]
wherein substituents R[0749] ₁and R₂are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXI)₆₀₂.
Table 603: A further preferred group of compounds of formula XXXIX corresponds to the general formula [0750]
wherein substituents R[0751] ₁and R₂are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXIX₆₀₃.
Table 604: A further preferred group of compounds of formula XXXIX corresponds to the general formula [0752]
wherein substituents R[0753] ₁and R₂are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXIX₆₀₄.
Table 605: A further preferred group of compounds of formula XXXIX corresponds to the general formula [0754]
wherein substituents R[0755] ₁and R₂are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXIX₆₀₅.
Table 606: A further preferred group of compounds of formula XXXIX corresponds to the general formula [0756]
wherein substituents R[0757] ₁and R₂are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXIX₆₀₆.
Table 607: A further preferred group of compounds of formula XXXIX corresponds to the general formula [0758]
wherein substituents R[0759] ₁and R₂are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXIX₆₀₇.
Table 608: A further preferred group of compounds of formula XXXIX corresponds to the general formula [0760]
wherein substituents R[0761] ₁and R₂are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXIX₆₀₈.
Table 609: A further preferred group of compounds of formula XXXIX corresponds to the general formula [0762]
wherein substituents R[0763] ₁and R₂are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXIX₆₀₉.
Table 610: A further preferred group of compounds of formula XXXIX corresponds to the general formula [0764]
wherein substituents R[0765] ₁and R₂are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXIX₆₁₀.
Table 611: A further preferred group of compounds of formula XXXIX corresponds to the general formula [0766]
wherein substituents R[0767] ₁and R₂are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXIX₆₁₁.
Table 612: A further preferred group of compounds of formula XXXIX corresponds to the general formula [0768]
wherein substituents R[0769] ₁and R₂are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXIX₆₁₂.
Table 613: A further preferred group of compounds of formula XXXIX corresponds to the general formula [0770]
wherein substituents R[0771] ₁and R₂are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXIX₆₁₃.
Table 614: A further preferred group of compounds of formula XXXIX corresponds to the general formula [0772]
wherein substituents R[0773] ₁and R₂are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXIX₆₁₄.
Table 615: A further preferred group of compounds of formula XXXIX corresponds to the general formula [0774]
wherein substituents R[0775] ₁and R₂are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXIX₆₁₅.
Table 616: A further preferred group of compounds of formula XXXIX corresponds to the general formula [0776]
wherein substituents R[0777] ₁and R₂are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXIX₆₁₆.
Table 617: A preferred group of compounds of formula XXXX corresponds to the general formula [0778]
wherein substituents R[0779] ₁and R₂are defined in Table A, constituting the disclosure of 34 specific compounds of formula XXXX₆₁₇.
Table 618: A further preferred group of compounds of formula XXXX corresponds to the general formula [0780]
wherein substituents R[0781] ₁and R₂are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXX₆₁₈.
Table 619: A further preferred group of compounds of formula XXXX corresponds to the general formula [0782]
wherein substituents R[0783] ₁and R₂are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXX₆₁₉.
Table 620: A further preferred group of compounds of formula XXXX corresponds to the general formula [0784]
wherein substituents R[0785] ₁and R₂are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXX₆₂₀.
Table 621: A further preferred group of compounds of formula XXXX corresponds to the general formula [0786]
wherein substituents R[0787] ₁and R₂are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXX₆₂₁.
Table 622: A further preferred group of compounds of formula XXXX corresponds to the general formula [0788]
wherein substituents R[0789] ₁and R₂are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXXX₆₂₂.
Table 623: A further preferred group of compounds of formula XXXX corresponds to the general formula [0790]
wherein substituents R[0791] ₁and R₂are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXX₆₂₃.
Table 624: A further preferred group of compounds of formula XXXX corresponds to the general formula [0792]
wherein substituents R[0793] ₁and R₂are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXX₆₂₄.
Table 625: A further preferred group of compounds of formula XXXX corresponds to the general formula [0794]
wherein substituents R[0795] ₁and R₂are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXX₆₂₅.
Table 626: A further preferred group of compounds of formula XXXX corresponds to the general formula [0796]
wherein substituents R[0797] ₁and R₂are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXX₆₂₆.
Table 627: A further preferred group of compounds of formula XXXX corresponds to the general formula [0798]
wherein substituents R[0799] ₁and R₂are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXX₆₂₇.
Table 628: A further preferred group of compounds of formula XXXX corresponds to the general formula [0800]
wherein substituents R[0801] ₁and R₂are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXX₆₂₈.
Table 629: A further preferred group of compounds of formula XXXX corresponds to the general formula [0802]
wherein substituents R[0803] ₁and R₂are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXX₆₂₉.
Table 630: A further preferred group of compounds of formula XXXX corresponds to the general formula [0804]
wherein substituents R[0805] ₁and R₂are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXx₆₃₀.
Table 631: A further preferred group of compounds of formula XXXIX corresponds to the general formula [0806]
wherein substituents R[0807] ₁and R₂are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXIX631.
Table 632: A further preferred group of compounds of formula XXXX corresponds to the general formula [0808]
wherein substituents R[0809] ₁and R₂are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXX₆₃₂.
Table 633: A further preferred group of compounds of formula XXXX corresponds to the general formula [0810]
wherein substituents R[0811] ₁and R₂are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXX₆₃₃.
Table 634: A further preferred group of compounds of formula XXXX corresponds to the general formula [0812]
wherein substituents R[0813] ₁and R₂are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXX₆₃₄.
Table 635: A further preferred group of compounds of formula XXXX corresponds to the general formula [0814]
wherein substituents R[0815] ₁and R₂are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXX₆₃₅.
Table 636: A further preferred group of compounds of formula XXXX corresponds to the general formula [0816]
wherein substituents R[0817] ₁and R₂are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXX₆₃₆.
Table 637: A further preferred group of compounds of formula XXXX corresponds to the general formula [0818]
wherein substituents R[0819] ₁and R₂are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXX₆₃₇.
Table 638: A further preferred group of compounds of formula XXXX corresponds to the general formula [0820]
wherein substituents R[0821] ₁and R₂are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXX₆₃₈.
Table 639: A further preferred group of compounds of formula XXXX corresponds to the general formula [0822]
wherein substituents R[0823] ₁and R₂are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXX₆₃₉.
Table 640: A further preferred group of compounds of formula XXXX corresponds to the general formula [0824]
wherein substituents R[0825] ₁and R₂are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXX₆₄₀.
Table 641: A preferred group of compounds of formula XXXIX corresponds to the general formula [0826]
wherein substituents R[0827] ₁and R₂are defined in Table A, constituting the disclosure of 34 specific compounds of formula XXXIX₆₄₁.
Table 642: A further preferred group of compounds of formula XXXIX corresponds to the general formula [0828]
wherein substituents R[0829] ₁and R₂are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXIX₆₄₂.
Table 643: A further preferred group of compounds of formula XXXIX corresponds to the general formula [0830]
wherein substituents R[0831] ₁and R₂are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXIX₆₄₃.
Table 644: A further preferred group of compounds of formula XXXIX corresponds to the general formula [0832]
wherein substituents R[0833] ₁and R₂are defined in Table B, constituting the disclosure of 34 specific compounds of formula
Table 645: A further preferred group of compounds of formula I corresponds to the general formula [0834]
wherein substituents R[0835] ₁and R₂are defined in Table A, constituting the disclosure of 34 specific compounds of formula XXXIX₆₄₅.
Table 646: A further preferred group of compounds of formula I corresponds to the general formula [0836]
wherein substituents R[0837] ₁and R₂are defined in Table A, constituting the disclosure of 34 specific compounds of formula XXXIX₆₄₆.
Table 647: A further preferred group of compounds of formula I corresponds to the general formula [0838]

wherein substituents R ₁and R₂are defined in Table A, constituting the disclosure of 34 specific compounds of formula XXXIX₆₄₇.

TABLE B


Cpmd no.	R₁	R₂

.001	F	Cl
.002	F	CN
.003	F	OCH₃
.004	F	OCF₃
.005	F	CF₃
.006	F	Br
.007	F	NO₂
.008	F	CH₃
.010	F	OCH₂C≡CH
.011	Cl	CN
.012	Cl	OCH₃
.013	Cl	OCF₃
.014	Cl	CF₃
.015	Cl	Br
.018	Cl	NO₂
.017	Cl	CH₃
.018	Cl	Cl
.019	Cl	CF₂H
.020	H	F
.021	H	Cl
.022	H	Br
.023	H	CF₃
.024	H	OCF₃
.025	H	NO₂
.026	H	CN
.027	H	i-Pr
.028	F	C₂H₅
.029	F	OCH₂CF₃
.030	H	OCH₂CF₃
.031	H	t-Bu
.032	F	t-Bu
.033	Cl	t-Bu
.034	H	J

TABLE C


Physicochemical data for prepared compounds from the above tables.
The figure before the point indicates the number of the table,
e.g. 1.004 means in Table 1 compound no. 004 of Table A and
634.001 means in Table 634 compound no. 001 of Table B.

Cmpd no.	physic. data

1.004	nD (40°C.) 1.5159
1.038	αD(20°C.) + 10.1°
1.352	m.p. 110-112°C.
35.004	¹H-NMR(CDCl₃): 8.11ppm(s, 1H); 7.80ppm(d, 1H);
	7.35ppm(s, 1H);4.46ppm(q, 2H);1.41ppm(t, 3H)
600.001	m.p. 133-134°C.
608.001	m.p. 91-93°C.
609.001	m.p. 114-116°C.
617.001	m.p. 143-145°C.
625.001	m.p. 140-143°C.
626.001	m.p. 143-145°C.
631.001	m.p. 154-157°C.
634.001	m.p. 162-164°C.

Examples of specific formulations for active ingredients of formula I, such as emulsifiable concentrates, solutions, wettable powders, coating granules, extruder granulates, dusts and suspension concentrates, are described in WO 97/34485 on pages 9-13. [0841]

BIOLOGICAL EXAMPLES

Example B1

Preemergence Herbicidal Action

Monocot and dicot test plants are sown in standard soil in plastic pots. Immediately after sowing, the plants are sprayed at a concentration of 2 kg active ingredient/ha with an aqueous suspension of the test compound prepared from a 25% wettable powder (Example F3, b)) according to WO 97/34485) or an emulsion of the test compound prepared from a 25% emulsifiable concentrate (Example F1 c)) according to WO 97/34485) (500 l of water/ha). The test plants are then cultivated in the greenhouse under optimum conditions. The test is evaluated 3 weeks later on a rating scale of 1-9 (1=total damage, 9=no action). Ratings of 1 to 4 (especially of 1 to 3) denote good to very good herbicidal action. [0842]
Test plants: Lolium, Setaria, Sinapis, Solanum, Ipomea. [0843]
The compounds of the invention show good herbicidal action. [0844]
An example of good herbicidal efficacy of compounds of formula I is given in Table B1. [0845]

TABLE B1

Pre-emergent action:

Test plant: Dose

Cmpd No. Lolium Setaria Sinapis Solanum Ipomea [g a.i./ha]

1.004 2 1 1 1 1 2000

1.038 7 1 1 2 3 2000

1.352 1 1 1 1 1 2000

Example B2

Post-emergent Herbicidal Action

In a greenhouse, monocot and dicot test plants are sown in standard soil in plastic pots and sprayed in the 4- to 6-leaf stage with an aqueous suspension of the test compounds of formula I prepared from a 25% wettable powder (Example F3, b) according to WO 97/34485) or with an emulsion of the test compound prepared from a 25% emulsifiable concentrate (Example F1 c)) according to WO 97/34485) at a concentration of 2 kg a.i./ha (500 l of water/ha). The test plants are then further cultivated in the greenhouse under optimum conditions. The test is evaluated about 18 days later on a rating scale of 1-9 (1=total damage, 9=no action). Ratings of 1 to 4 (especially of 1 to 3) denote good to very good herbicidal action. In this test the compounds of formula I exhibit a pronounced herbicidal action. Test plants: Lolium, Setaria, Sinapis, Solanum, Ipomea. In this test too the compounds of formula I exhibit a pronounced herbicidal action. An example of good herbicidal efficacy of compounds of formula I is given in Table B2. [0846]

TABLE B2

Post-emergente action:

Test plant: Dose

Cmpd No. Lolium Setaria Sinapis Solanum Ipomea [g a.i./ha]

1.004 1 1 1 1 1 2000

1.038 1 1 1 1 1 2000

1.352 1 1 1 1 1 2000
The active ingredients of formula I can also be used for weed control by mixing with known herbicides as co-herbicides, for example as ready-for-use formulations or as tank mix. Suitable compounds for mixing with active ingredients of formula I are for example the following co-herbicides: compound of formula I+acetochlor; compound of formula I+acifluorfen; compound of formula I+aclonifen; compound of formula I+alachlor; compound of formula I+ametryn; compound of formula I+aminotriazol; compound of formula I+amidosulfuron; compound of formula I+asulam; compound of formula I+atrazine; compound of formula I+BAY FOE 5043; compound of formula I+benazolin; compound of formula I+bensulfuron; compound of formula I+bentazone; compound of formula I+bifenox; compound of formula I+bispyribac sodium; compound of formula I+bialaphos; compound of formula I+bromacil; compound of formula I+bromoxynil; compound of formula I+bromophenoxim; compound of formula I+butachlor; compound of formula I+butylate; compound of formula I+cafenstrole; compound of formula I+carbetamide; compound of formula I+chloridazone; compound of formula I+chlorimuron ethyl; compound of formula I+chlorbromuron; compound of formula I+chlorsulfuron; compound of formula I+chlortoluron; compound of formula I+cinosulfuron; compound of formula I+clethodim; compound of formula I+clodinafop; compound of formula I+clomazone; compound of formula I+clopyralid; compound of formula I+cloransulam; compound of formula I+cyanazine; compound of formula I+cyhalofop; compound of formula I+dalapon; compound of formula I+2,4-D; compound of formula I+2,4-DB; compound of formula I+desmetryn; compound of formula I+desmedipham; compound of formula I+dicamba; compound of formula I+diclofop; compound of formula I+difenzoquat methyl sulfate; compound of formula I+diflufenican; compound of formula I+dimefuron; compound of formula I+dimepiperate; compound of formula I+dimethachlor; compound of formula I+dimethametryn; compound of formula I+dimethenamid; compound of formula I+S-dimethenamid; compound of formula I+dinitramine; compound of formula I+dinoterb; compound of formula I+dipropetryn; compound of formula I+diuron; compound of formula I+diquat; compound of formula I+DSMA; compound of formula I+EPTC; compound of formula I+esprocarb; compound of formula I+ethalfluralin; compound of formula I+ethametsulfuron; compound of formula I+ethephon; compound of formula I+ethofumesate; compound of formula I+ethoxysulfuron; compound of formula I+fenclorim; compound of formula I+flamprop; compound of formula I+fluazasulfuron; compound of formula I+fluazifop; compound of formula I+flumetralin; compound of formula I+flumetsulam; compound of formula I+fluometuron; compound of formula I+flurchloridone; compound of formula I+fluoxaprop; compound of formula I+fluroxypyr; compound of formula I+fluthiacet-methyl; compound of formula I+fluxofenim; compound of formula I+fomesafen; compound of formula I+glufosinate; compound of formula I+glyphosate; compound of formula I+halosulfuron; compound of formula I+haloxyfop; compound of formula I+hexazinone; compound of formula I+imazamethabenz; compound of formula I+imazapyr; compound of formula I+imazaquin; compound of formula I+imazethapyr; compound of formula I+imazosulfuron; compound of formula I+ioxynil; compound of formula I+isoproturon; compound of formula I+isoxaben; compound of formula I+isoxaflutole; compound of formula I+karbutylate; compound of formula I+lactofen; compound of formula I+lenacil; compound of formula I+linuron; compound of formula I+MCPP; compound of formula I+metamitron; compound of formula I+metazachlor; compound of formula I+methabenzthiazuron; compound of formula I+methazole; compound of formula I+metobromuron; compound of formula I+metolachlor; compound of formula I+S-metolachlor; compound of formula I+metosulam; compound of formula I+metribuzin; compound of formula I+metsulfuron methyl; compound of formula I+molinate; compound of formula I+MCPA; compound of formula I+MSMA; compound of formula I+napropamide; compound of formula I+NDA-402989; compound of formula I+n; compound of formula I+nicosulfuron; compound of formula I+norflurazon; compound of formula I+oryzalin; compound of formula I+oxadiazon; compound of formula I+oxasulfuron; compound of formula I+oxyfluorfen; compound of formula I+paraquat; compound of formula I+pendimethalin; compound of formula I+phenmedipham; compound of formula I+phenoxaprop-P-ethyl (R); compound of formula I+picloram; compound of formula I+pretilachlor; compound of formula I+primisulfuron; compound of formula I+prometon; compound of formula I+prometryn; compound of formula I+propachlor; compound of formula I+propanil; compound of formula I+propazine; compound of formula I+propaquizafop; compound of formula I+propyzamide; compound of formula I+prosulfuron; compound of formula I+pyrazolynate; compound of formula I+pyrazosulfuron ethyl; compound of formula I+pyrazoxyphen; compound of formula I+pyridate; compound of formula I+pyriminobac methyl; compound of formula I+pyrithiobac sodium; compound of formula I+quinclorac; compound of formula I+quizalofop; compound of formula I+rimsulfuron; compound of formula I+sequestren; compound of formula I+sethoxydim; compound of formula I+simetryn; compound of formula I+simazin; compound of formula I+sulcotrione; compound of formula I+sulfosate; compound of formula I+sulfosulfuron methyl; compound of formula I+tebutam; compound of formula I+tebuthiuron; compound of formula I+terbacil; compound of formula I+terbumeton; compound of formula I+terbuthylazin; compound of formula I+terbutryn; compound of formula I+thiazafluron; compound of formula I+thiazopyr; compound of formula I+thifensulfuron methyl; compound of formula I+thiobencarb; compound of formula I+tralkoxydim; compound of formula I+triallate; compound of formula I+triasulfuron; compound of formula I+trifluralin; compound of formula I+tribenuron methyl; compound of formula I+triclopyr; compound of formula I+triflusulfuron; compound of formula I+trinexapac ethyl, as well as esters and salts of these compounds for mixing with a compound of formula I, which named for example in The Pesticide Manual, Eleventh Edition, 1997, BCPC. [0847]

Claims

What is claimed is:

1. Compounds of formula I

R₁is hydrogen, fluorine, chlorine, bromine or methyl;

R₃is cyano or R₄C(O)—;

R₄is hydrogen, fluorine, chlorine, C₁-C₈alkyl, C₂-C₈alkenyl, C₂-C₈alkinyl, C₃-C₆cycloalkyl, C₁-C₈halogenalkyl, cyano-C₁-C₄alkyl, C₂-C₈halogenalkenyl, C₁-C₄alkoxy-C₁-C₄alkyl, C₃-C₆alkenyloxy-C₁-C₄alkyl, C₁-C₄alkylthio-C₁-C₄alkyl, phenyl, phenyl substituted once to three times by halogen, C₁-C₄alkyl or C₁-C₄halogenalkyl, benzyl or benzyl substituted once to three times on the phenyl ring by halogen, C₁-C₄alkyl or C₁-C₄halogenalkyl; or

R₃is R₅X₁C(O)—;

X₁is oxygen, sulfur,

R₅is hydrogen, C₁-C₈alkyl, C₃-C₈alkenyl, C₃-C₈alkinyl, C₃-C₆cycloalkyl, C₃-C₆cycloalkyl-C₁-C₁C₆alkyl, C₁-C₈halogenalkyl, C₃-C₈halogenalkenyl, cyano-C₁-C₄alkyl, C₁-C₄alkoxy-C₁-C₄alkyl, C₃-C₆alkenyloxy-C₁-C₄alkyl, (oxiranyl)-CH₂—oxetanyl-, C₁-C₄alkylthio-C₁-C₄alkyl, phenyl, phenyl substituted once to three times by halogen, C₁-C₄alkyl or C₁-C₄halogenalkyl, benzyl or benzyl substituted once to three times on the phenyl ring by halogen, C₁-C₄alkyl or C₁-C₄-

R₈is hydrogen, C₁-C₈alkyl, C₃-C₈alkenyl, C₃-C₈alkinyl, C₃-C₆cycloalkyl, C₁-C₈halogenalkyl, C₃-C₈halogenalkenyl, cyano-C₁-C₄alkyl, C₁-₄alkoxy-C₁-C₄alkyl, C₃-C₆alkenyloxy-C₁-C₄alkyl, (oxiranyl)-CH₂-, oxetanyl, C₁-C₄alkylthio-C₁-C₄alkyl, phenyl, phenyl substituted once to three times by halogen, C₁-C₄alkyl or C₁-C₄halogenalkyl, benzyl, benzyl substituted once to three times on the phenyl ring by halogen, C₁-C₄alkyl or C₁-C₄halogenalkyl, or phenyl-C₂-C₆alkyl;

R₆, R₇, R₉and R₁₀are independently of one another hydrogen, C₁-C₈alkyl, C₃-C₈alkenyl, C₃-C₈alkinyl, C₁-C₈halogenalkyl or benzyl; or

R₃is B₁—C₁-C₈alkyl, B₁—C₂-₈alkenyl, B₁—C₂-C₈alkinyl, B₁—C₁-C₈halogenalkyl, B₁—C₂-C₈halogenalkenyl, B₁—C₁-C₄alkoxy-C₁-C₄alkyl, B₁—C₁-C₄alkylthio-C₁-C₄alkyl or B₁—C₃-C₆cycloalkyl;

B₁is hydrogen, cyano, hydroxy, C₁-C₈alkoxy, C₃-₈alkenyloxy, R₁₁X₃C(O)—, C₁-C₄alkylcarbonyl or C₁-C₄halogenalkylcarbonyl;

X₃has the same meaning as X₂;

R₁₁has the same meaning as R₈; or

R₃is B₂—C(R₁₂)═CH—;

B₂is nitro, cyano or R₁₃X₄C(O)—;

R₁₂is cyano or R₁₄X₅C(O)—;

X₄and X₅have the same meaning as X₂; and

R₁₃and R₁₄have the same meaning as R₈;

R₁₅is C₁-C₃alkyl, C₁-C₃halogenalkyl or amino;

R₁₆is C₁-C₃halogenalkyl, C₁-C₃alkyl-S(O)_n1, C₁-C₃halogenalkyl-S(O)_n1or cyano; or

R₁₆and R₁₅together form a C₃- or C₄alkylene or C₃- or C₄alkenylene bridge which may be substituted by halogen, C₁-C₃halogenalkyl or cyano;

n, is 0, 1 or 2;

R₁₇is hydrogen, C₁-C₃alkyl, halogen, C₁-C₃halogenalkyl or cyano; or

R₁₇and R₁₆together form a C₃- or C₄alkylene or C₃-or C₄alkenylene bridge which may be substituted by halogen, C₁-C₃halogenalkyl or cyano;

R₁₈is hydrogen, C₁-C₃alkyl, halogen or cyano;

R₁₉is C₁-C₃halogenalkyl; or

R₁₉and R₁₈together form a C₃- or C₄alkylene or C₃-or C₄alkenylene bridge which may be substituted by halogen, C₁-C₃halogenalkyl or cyano;

R₂₀is hydrogen or C₁-C₃alkyl or halogen; or

R₂₀and R₁₉together form a C₃- or C₄alkylene or C₃- or C₄alkenylene bridge which may be substituted by halogen, C₁-C₃halogenalkyl or cyano;

R₂₁is hydrogen, C₁-C₃alkyl, halogen, C₁-C₃halogenalkyl, R₄₀O—, R₄₁S(O)_n2, R₄₂(R₄₃)N, R₄₅(R₄₆)N—C(R₄₄)═N—, hydroxy, nitro or N≡C—S—;

R₄₀is C₁-C₃alkyl, C₁-C₃halogenalkyl, C₂-C₄alkenyl, C₃- or C₄alkinyl or C₁-C₅alkoxycarbonyl-C₁-C₄alkyl;

R₄₁is C₁-C₄alkyl or C₁-C₄halogenalkyl;

n₂is 0, 1 or 2;

R₄₂is hydrogen, C₁-C₄alkyl, C₁-C₄halogenalkyl, C₃-C₆cycloalkyl, OHC— or C₁-C₄alkylcarbonyl;

R₄₃, R₄₄, and R₄₆are independently of one another hydrogen or C₁-C₄alkyl;

R₄₅is C₁-C₄alkyl;

R₂₂is hydrogen, C₁-C₄alkyl, halogen, C₁-C₄halogenalkyl, C₂-C₄alkenyl, C₃-C₅halogenalkenyl,

C₃- or C₄alkinyl, C₁-C₄alkoxy, C₁-C₄alkylcarbonyl, C₁-C₄halogenalkylcarbonyl, C₂-C₄alkenylcarbonyl, C₂-C₄halogenalkenylcarbonyl, C₂-C₄alkinylcarbonyl, C₂-C₄halogenalkinylcarbonyl, C₁-C₄alkylcarbamoyl, C₁-C₄alkylS(O)_n3, C₃- or C₄alkinylS(O)_n3, OHC—, nitro, amino, cyano or N≡C—S—;

n₃is 0, 1 or 2;

R₂₃and R₂₄are independently of one another hydrogen, C₁-C₄alkyl, halogen, C₁-C₄halogen-alkyl or cyano;

R₂₅and R₂₆are independently of one another hydrogen, methyl, halogen, hydroxy or ═O;

R₂₇and R₂₈are independently of one another hydrogen, C₁-C₄alkyl or C₁-C₄halogenalkyl;

R₂₉and R₃₀are independently of one another hydrogen, C₁-C₃alkyl or halogen;

R₃₁and R₃₂are independently of one another hydrogen or C₁-C₄alkyl; or

R₃₁and R₃₂together form the group

R₄₇and R₄₈are independently of one another C₁-C₄alkyl; or

R₄₇and R₄₈together form a C₄or C₅alkylene bridge;

R₃₃is hydrogen or C₁-C₃alkyl; or

R₃₃together with R₃₂forms a C₃-C₅alkylene bridge which may be broken by oxygen and/or substituted by halogen, C₁-C₄alkyl, C₂-C₄alkenyl, C₁-C₃alkylcarbonyloxy, C₁-C₃alkylsulfonyloxy, hydroxy or ═O;

R₃₄, R₃₅, R₃₆and R₃₇are independently of one another hydrogen, C₁-C₃alkyl, C₃- or C₄alkenyl or C₃-C₅alkinyl; or

R₃₄and R₃₅on the one hand and R₃₆and R₃₇on the other each form a C₂-C₅alkylene or C₃-C₅alkenylene bridge together, which may be broken by oxygen, —C(O)—, sulfur, or —S(O)₂—;

R₃₈is hydrogen, C₁-C₄alkyl, C₁-C₄halogenalkyl, C₃- or C₄alkenyl or C₃- or C₄alkinyl;

R₃₉is hydrogen, C₁-C₄alkyl, C₁-C₃alkoxy-C₁- or -C₂alkyl, C₁-C₄halogenalkyl, C₃- or or C₄alkenyl, C₃-C₄halogenalkenyl or C₃- or C₄alkinyl; or

R₃₉and R₃₈together form a C₃-C₅alkylene bridge; and

X₆, X₇, X₈, X₉, X₁₀, X₁₁, X₁₂, X₁₃, X₁₄, X₁₅, X₁₆, X₁₇, X₁₈and X₁₉are independently of one another oxygen or sulfur,

and the agrochemically acceptable salts and stereoisomers of these compounds of formula I

2. Compounds of formula I of claim 1, wherein R₂is methyl, halogen, hydroxy, nitro, amino or cyano.

3. A method for the preparation of compounds of formula I,

wherein R₁, R₂, R₃, A and W are as defined in claim 1, comprising treating a compound of formula II

wherein R₁, R₂and W have the meanings indicated, and L₄is a leaving group, either

a) in a suitable solvent, where appropriate in the presence of a base, a catalyst and a compound of formula V

R₅—OH (V),

wherein R₅is hydrogen or C₁-C₄alkyl, under positive pressure with carbon monoxide, or

b) in a suitable solvent in the presence of a tertiary amine, a catalyst, and an olefin by means of the Heck reaction, or under said conditions by means of reaction with a Grignard reagent of formula Va

R₃—Mg-halogenide (Va),

wherein R₃is B₁—C₁-C₈alkyl, B₁—C₂-C₈alkenyl, B₁—C₂-C₈alkinyl, B₁—C₁-C₈halogenalkenyl, B₁—C₂-C₈halognealkenyl, B₁—C₁-C₄alkoxy-C₁-C₄alkyl, B₁—C₁-C₄alkylthio-C₁-C₄alkyl or B₁—C₃-C₆cycloalkyl and B₁has the meaning defined in claim 1, or in an inert solvent and in the presence of a catalyst with a tin compound of formula Vb

(R₃)₄Sn (Vb),

wherein R₃has the meaning indicated, or

c) where applicable in an inert solvent at reaction temperatures of 20-300° C. subjecting said compound to a cyanidation reaction, or

d) first oxidizing said compound in a suitable solvent to form a compound of formula IV

and treating this in an inert solvent with dimethylcarbamoyl chloride and a cyanidation reagent, and then where applicable further functionalizing the compound according to the definitions of A and R₃.

4. Compounds of formula II

wherein R₁and R₂are as defined in claim 1, W is a W₃, W₄, W₅, W₆, W₉or W₁₀group and L₄is a leaving group.

5. A herbicidal and plant growth inhibiting composition, which comprises a herbicidally effective amount of the compound of formula I on an inert carrier.

6. A herbicidal and plant growth inhibiting composition of claim 5 comprising as an additional component a further co-herbicide.

7. A method of controlling undesirable plant growth, which comprises treating the plants or the locus thereof with a herbicidally effective amount of a compound of formula I or of a composition containing such a compound.

8. Use of a composition according to claim 5 for controlling undesirable plant growth.